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Resumen
Introducción - Las herramientas educativas en línea permiten una formación médica
interactiva para estudiantes dispersos geográﬁcamente. Pocos estudios tienen como objetivo
primario su validación objetiva. Por sus ventajas logísticas, se utilizó un taller de delineación
en línea (TDE) para homogeneizar el contorneo como control de calidad de radioterapia en
el ensayo prospectivo multicéntrico europeo RAIDs (Rational molecular Assessments and
Innovative Drug Selection) en cáncer de cérvix localmente avanzado (CCLA). Se realizaron
dos TDE idénticos para evaluar sobre un paciente de simulacro las delineaciones de los
centros RAIDs.
Objetivos
• Principales:
1. Realizar una validación interobservadora de los TDE en CCLA mediante una eval-
uación cualitativa y cuantitativa de la mejoría de delineaciones entre participantes
(variabilidad interobservadora).
2. Efectuar una validación intraobservadora del TDE en CCLA mediante una evalu-
ación cualitativa y cuantitativa de la mejoría de delineaciones de cada participante
(variabilidad intraobservadora).
• Secundarios:
1. Evaluar la metodología de enseñanza del TDE mediante cuestionarios de satisfac-
ción.
2. Análizar las delineaciones de los participantes de los centros europeos que utilizan
la resonancia magnética para planiﬁcar braquiterapia (BQT) con respecto a los
que no la usan.
Metodología - Se realizaron dos TDE incluyendo 46 especialistas de 14 centros de
RAIDs. Se estableció una colaboración técnica con la Sociedad Europea de Oncología Ra-
dioterápica (ESTRO). La formación se realizó por una experta en la materia, CHM. Mediante
3 presentaciones en directo en línea se presentaron la plataforma de contorneo Fellowship
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in Anatomical deLineation and CONtouring (FALCON) EduCaseTM, las guías de delin-
eación y los contornos de los participantes. Los participantes completaron contornos basales
(C1), guía (C2) y ﬁnales (C3) para radioterapia externa (RTE) y braquiterapia (BQT)
en CCLA. La variabilidad interobservadora e intraobservadora se evaluó cuantitativamente
(Índice DICE) y se analizaron mediante un modelo lineal mixto. La variabilidad intraobser-
vadora fue evaluada cualitativamente mediante el test de McNemar.
Resultados - Nueve participantes enviaron contornos para RTE y BQT (C1-C3). Treinta
y dos envió algún contorno. La comparación interobservadora cuantitativa de RTE mostró
una mejoría signiﬁcativa entre C2 y C1 para intestino, CTV ganglionar, CTV-p y GTV-
ganglio con un detrimento signiﬁcativo para GTV-ganglio (entre C3 y C1; C2), CTV-p
(entre C3 y C2) e intestino (entre C3 y C2), es decir, una mejoría en general entre C2 y
C1, con un detrimento signiﬁcativo entre C3 y C2 en dos volúmenes blanco y un órgano
de riesgo. Para BQT hubo una mejoría signiﬁcativa entre C2 y C1 para vejiga, GTV, HR-
CTV e IR-CTV con un detrimento signiﬁcativo para vejiga (entre C3 y C2), en resumen,
una mejoría general entre C2 y C1, con sólo un detrimento entre C3 y C2 para la vejiga.
Las comparaciones intraobservadoras cuantitativas mostraron una mejoría signiﬁcativa de
delineaciones de regiones de interés entre C2 y C1, C3 y C1 y C3 y C2 para RTE y entre
C2 y C1 para BQT. Las comparaciones cualitativas intraobservadoras destacables en BQT
fueron una mejoría signiﬁcativa en las direcciones derecha y posterolateral derecha para los
volúmenes blanco entre C2 y C1, que pasaron a ser signiﬁcativamente peores para estas
direcciones entre C3 y C1; C2. El resultado de las preguntas acerca de la organización y
el contenido del TDE del cuestionario de satisfacción (escala del 1 al 5, 1=poco satisfecho,
5=muy satisfecho) para los 20 participantes que respondieron fue de media 4.36 (rango:
3.95-4.60). Los centros que empleaban resonancia magnética para la delineación en BQT
tuvieron una mejoría signiﬁcativa para HR-CTV con respecto a los que usaban otras técnicas
(entre C2 y C1: p-value < 0.005; entre C3 y C1: p-value = 0.02).
Conclusiones - Los TDE permiten formar, armonizar inicialmente la delineación y eval-
uar la experiencia de los centros antes de la inclusión de pacientes de una forma cómoda y
eﬁcaz en el seno de un estudio multicéntrico.
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Summary
Introduction - E-learning programmes allow eﬀective medical training for geographi-
cally dispersed participants. Few studies aim primarily to validate these programmes objec-
tively. Considering its logistical aptitudes, an ODW using FALCON was used to homogenise
delineation practice in cervical cancer as quality control among European centres partici-
pating in a multicentre prospective trial on locally advanced cervical cancer (LACC). Two
identical ODW were performed, to evaluate the delineations of RAIDs centres on a ﬁctitious
patient.
Aims
• Primary endpoints:
1. Interobserver validation of the ODW in LACC by using qualitative and quan-
titative assessments of the improvement of clinician contours between clinicians
(interobserver variability).
2. Intraobserver validation of the ODW in LACC by assessing qualitatively and
quantitatively the improvement of the clinician contours for each clinician (in-
traobserver variability).
• Secondary endpoints:
1. Evaluation of the teaching methodology of the ODW as reﬂected by the partici-
pant satisfaction questionnaires.
2. Analysis of clinician contouring on magnetic resonance imaging (MRI) for Euro-
pean centres which use MRI for brachytherapy planning versus those which do
not.
Methods - Two ODW included 46 clinicians from 14 RAIDs centres. A technical col-
laboration was established with European Society for Radiotherapy & Oncology (ESTRO).
Training was performed by an expert in the ﬁeld, CHM. Through 3 live online presentations,
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the contouring platform FALCON EduCaseTM, the delineation guidelines and the partic-
ipant contours were presented. Participants were asked to complete baseline contouring
(C1), guideline contouring (C2) and ﬁnal contouring (C3) for external beam radiotherapy
(EBRT) and brachytherapy (BT) for LACC. Interobserver and intraobserver variability was
quantitatively evaluated (DICE index) and analysed by a linear mixed model. Intraobserver
variability was qualitatively evaluated by the McNemar test.
Results - Nine participants contoured for EBRT and BT for C1 - C3. Thirty-two
clinicians submitted any contour.
Concerning interobserver quantitative comparisons for EBRT, signiﬁcant improvement
was observed for C2 vs. C1 for bowel, nodal elective volume (CTV-node), GTV-p, uterus and
vagina, at least 20 mm below GTV-p (CTV-p) and radiologically pathological lymph nodes
to boost (GTV-node), versus a signiﬁcant detriment for GTV-node (C3 vs. C1; C2), CTV-p
(C3 vs. C2) and bowel (C3 vs. C2), showing overall an improvement in C2 vs. C1, versus a
detriment in C3 vs. C2 for two target volumes and one organ at risk. In the BT treatment
there was signiﬁcant improvement for C2 vs. C1 for bladder, gross tumor volume (GTV), high
risk CTV (HR-CTV) and intermediate risk CTV (IR-CTV), versus a signiﬁcant detriment for
bladder (C3 vs. C2), thus a general improvement in C2 vs. C1, with only a detriment in C3
vs. C2 for bladder. As for intraobserver quantitative comparisons, a signiﬁcant improvement
was observed for contouring a region of interest between C2 vs. C1, C3 vs. C1 and C3 vs. C2
for EBRT and between C2 vs. C1 for BT. Notable intraobserver qualitative comparisons were
found for BT, a signiﬁcant improvement towards the right and posterolateral right directions
for target volumes in C2 vs. C1, which became signiﬁcantly worse in these directions in C3
vs. C1 and C2. The average result of the Organisation and Content items in the satisfaction
questionnaire for the 20 ODW participants who responded (scale 1-5, 1=poor, 5=excellent)
was 4.36 (range 3.95-4.60). With regard to the imaging technique used for BT planning,
centres using magnetic resonance imaging (MRI) did signiﬁcantly better in the BT case for
HR-CTV than centres using other techniques (C2 vs. C1: p-value < 0.005; C3 vs. C1:
p-value = 0.02).
Conclusions - ODW allow to train, initially harmonise contouring and assess the ex-
perience of centres before patient inclusion conveniently and eﬃciently in the context of a
multicentre trial.
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1.1 General context: cervical cancer
1.1.1 Epidemiology
Even nowadays, when screening programmes for cervical cancer are readily accessible to
women in developed countries, this illness still accounts for a non-negligible morbidity and
mortality in Europe. Ferlay et al., (2015) have found it ranks globally as the fourth in Europe
and as the sixth most frequent cancer in women. When considering emerging countries, it is
currently the second most common female cancer, as it used to be worldwide in 1975. There
were an estimated 58,400 new cases in 2012 in Europe, with 33,900 occurring in Central and
Eastern Europe. In terms of mortality, the estimated number of deaths from cervical cancer
in 2012 was 24,400 women in Europe, of which 15,400 were in Central and Eastern Europe,
and only 3,500 in Western Europe. This data highlights a notable imbalance between these
European regions.
The EUROCARE-5 study investigated the imbalance in survival among European regions
for female breast and genital cancers. For cervical cancer, they found poor survival in Eastern
Europe with an augmentation of the incidence in several Eastern European countries, as
opposed to an incidence which was either reduced or maintained stable in the majority
of other European countries. The authors believe these diﬀerences might be due to either
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deﬁcits in screening/prompt diagnosis, suboptimal treatment, or a combination of both (Sant
et al., 2015).
A recent publication which considered inferences for Eastern European countries based
on the epidemiological changes of cervical cancer over time in Bulgaria suggested that other
Eastern European countries adopt the actions taken there to decline its incidence, such as the
intensiﬁcation of screening (Samson et al., 2016). They even consider a common prevention
programme for all Eastern European countries. Another of their proposals was for Eastern
European countries to improve treatment accessibility in order to achieve lower rates of
mortality.
Survival has been found to be clearly linked with the International Federation of Gyne-
cology and Obstetrics (FIGO) classiﬁcation staging at diagnosis, with rates varying between
93% survival in stage IA and 15% in stage IVb (Reuzé et al., 2017).
Several risk factors have been linked to cervical cancer, such as oral contraception (used
over 5 years), having a transplanted organ, human immunodeﬁciency virus (HIV) infection,
active or passive smoking, engaging in sexual intercourse at an early age, having a large
amount of sexual partners, multiparity and a family member of the ﬁrst degree aﬀected by
cervical cancer. These factors may favor infection by the human papillomavirus (HPV),
which causes the vast majority of cervical cancer cases, or facilitate the development of
cervical cancer (Hillemanns et al., 2016; Lea and Lin, 2012). In the presence of a sustained
infection by HPV, the average time between viral acquisition and the appearance of cervical
intraepithelial neoplasia (CIN) and ultimately cervical cancer is of 15 years (Lea and Lin,
2012). The development of cervical cancer can also be due to female hormones, with most
cases presenting above 45 years of age (Plummer et al., 2012; Pike et al., 2004).
HPV vaccine
The ﬁrst widely used HPV vaccine only included subtypes 16 and 18 (some also 6 and
11). Although approximately 70% of cervical cancer cases are caused by subtypes 16 and
18, there was still a need to increase the coverage to prevent even more cases (Hillemanns et
al., 2016). Thus, in 2015, the European Medicines Agency recommendations included a new
vaccine ensuring protection from 9 HPV subtypes causing 90% of cervical cancer cases (Joura
et al., 2015). The other advantage of this vaccine is that it is administered in 2 as opposed to
3 doses, thus facilitating adherence. Currently, the rates of women vaccinated diﬀer greatly
between European countries. The amount of national school vaccination plans oscillate
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between under 30% and over 80% (Hillemanns et al., 2016). These school programmes are
of utmost importance as vaccination has better results before sexarche (indication in women
between 9 and 26 years old). In spite of HPV vaccination, these women still must be screened
routinely by the papanicolau test (Pap smear), as unfortunately not all HPV subtypes which
may induce cervical cancer are covered (Lea and Lin, 2012).
Screening
Although prevention by vaccination is beginning to play a role in reducing the incidence of
cervical cancer, screening programmes are still quite necessary. Traditional routine screening
has consisted of the Pap smear technique, which does not have a high sensitivity (55% to
80%) and only detects accurately stage I cervical cancer in 30-50% of cases (Benoit et al.,
1984). To improve this technique an option is liquid-based cytology, allowing better sample
quality, therefore improving its interpretation in less time (Hillemanns et al., 2016).
Recently, HPV testing has been introduced in some national screening programmes, for
instance, Germany. This is based on the evidence drawn from long term follow up of patients
included in four major randomised European trials initially powered to distinguish diﬀer-
ences in detection of precancerous cervical lesions between the Pap smear and HPV testing
techniques (Ronco et al., 2014). With a median follow up of 6.5 years, the pooled results
(intention to screen) of the Dutch (POBASCAM), Italian (NTCC), Swedish (Swedescreen)
and British (ARTISTIC) studies were in favour of HPV testing for screening, protecting from
cervical cancer 60-70% better than the cytology technique. This is due to a higher diagnosis
of precancerous lesions at ﬁrst screening, before progression. As new HPV infections often
are transitory and CIN lesions in regression may be overdiagnosed, the time between HPV-
screenings may be incremented to 5 years, resulting in less colposcopies and biopsies than
with cytologies (more cost-eﬀective) (Ronco et al., 2014). An interesting point was raised in
the ARTISTIC trial (Kitchener et al., 2008)when assessing psychological distress amongst
study subjects (Generalised Health Questionnaire-28). There was no signiﬁcant diﬀerence in
distress between patients who had an HPV-test and a cytology versus those who only had a
cytology (Kitchener et al., 2008). Psychological distress is an important factor to consider
in screening programmes, and these results are encouraging for the use of HPV-testing in
cervical cancer screening from the psychosocial point of view.
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1.1.2 Treatment modalities
Current guidelines include surgical or radiotherapy options for early stage cervical can-
cer, up to stage IB1 (Koh et al., 2017). Stage IA1 may be treated by conization or simple
hysterectomy, but if there is lymphovascular invasion (LVI) there is a slightly larger risk of
lymphatic spread (5%), thus a modiﬁed radical hysterectomy with pelvic lymphadenectomy
is recommended (Lea and Lin, 2012; Koh et al., 2017). From two factors indicating higher
risk of recurrence (LVI, large tumour size, deep invasion of stroma) an option is to administer
adjuvant pelvic radiation therapy with or without concurrent cisplatin (Haie-Meder et al.,
2010a). In stage IA2 cervical cancer standard treatment is modiﬁed radical hysterectomy
with pelvic lymphadenectomy, although fertility sparing techniques include conization or
trachelectomy. When unfortunately surgery results in margins which are positive, or evi-
dences involvement of either the parametria or pelvic lymph nodes, there is an indication for
postoperative radiochemotherapy in stage IA1 and IA2 tumours (Haie-Meder et al., 2010a).
In both stages IA1 and IA2 without LVI, in unsuitable candidates for surgery, an alternative
is brachytherapy (BT) (Lea and Lin, 2012; Koh et al., 2017). Several treatment options may
be proposed to treat stage IB1 cervical cancer. The surgical option is radical hysterectomy
with bilateral oophorectomy and pelvic lymph node dissection. Fertility sparing treatment
by radical trachelectomy is also a possibility in young patients with very good prognostic
features (smaller than 2 cm, no LVI and negative lymph nodes). Another option is pelvic
external beam radiotherapy (EBRT) with or without concurrent chemotherapy followed by
intracavitary BT (Haie-Meder et al., 2010a; Koh et al., 2017). A last possibility is either
preoperative BT with surgery after 6-8 weeks or radiochemotherapy, BT and surgery (Haie-
Meder et al., 2010a; Koh et al., 2017). As in stages IA1 and IA2, in those patients who
were operated in ﬁrst intent, but whose surgical margins were positive, or had parametrial
or pelvic lymph node involvement, postoperative radiochemotherapy should be administered
(Haie-Meder et al., 2010a).
Concurrent chemoradiotherapy is the standard of care for locally advanced cervical cancer
(LACC), FIGO stages IB2 through IVA (Haie-Meder et al., 2010a; Koh et al., 2017). As
this thesis was centred on LACC, this section will elaborate on its treatment. Five diﬀerent
randomised trials have found a reduction in the risk of death of 30-50% when concurrent
chemoradiotherapy using cisplatin was administered (Table 1.1) (Koh et al., 2017). A meta-
analysis of 18 studies including data from 3,452 patients showed that in the 13 trials which
compared the same radiotherapy treatment with chemoradiation there was a 6% higher
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5-year survival, with an even higher 5-year survival improvement of 19% in two studies
which added adjuvant chemotherapy after chemoradiation (Vale, 2008). This indication
was reinforced by the results from a registry of the Canadian population, including 4,069
patients diagnosed with cervical cancer. Three-year overall survival went from 58.6% in
the time period when patients received radiation alone (1995-1998) to 69.8% when they
received chemoradiation (1999-2001) (Pearcey et al., 2007). Thus, the survival beneﬁt with
chemoradiation has been thoroughly established, which outweighs its higher rates of acute
toxicity, especially haematological and of the digestive tract (Haie-Meder et al., 2010a).
Study n Median
follow-up
FIGO Control Comparison RR for
death
Stehman et al., (2007) 369 8.4 IB2 RT RT + weekly cisplatin 0.63
Rose et al., (2007) 526 8.8 IIB-IVA RT + Hydroxyurea RT + weekly cisplatin
RT + cisplatin + 5-FU
+ hydroxyurea
0.57
0.51
Eifel et al., (2004) 228 6.6 IB-IVA Extended ﬁeld RT RT + cisplatin + 5-FU 0.49
Whitney et al., (1999) 368 8.7 IIB-IVA RT + Hydroxyurea RT + cisplatin + 5-FU 0.72
W. A. Peters et al., (2000) 243 3.5 IB or IIA
(post-operative
selection)
RT RT + cisplatin + 5-FU 0.50
Table 1.1: Estimates of the Relative Risk (RR) of Death in Five Clinical Trials of Concurrent Chemotherapy and Radiotherapy
(adapted from Koh et al., (2017)).
Chemoradiation is administered by EBRT followed by intracavitary BT, with concurrent
chemotherapy, most often cisplatin-based. Improvements in each of these treatments are
leading to the optimisation of this therapy. Thus, the use of intensity modulated radiother-
apy (IMRT) reduces toxicity of the digestive tract while allowing dose escalation (Marnitz et
al., 2011; Gandhi et al., 2013). The most relevant improvement in the BT ﬁeld has been the
incorporation of image guided brachytherapy (IGBT), which not only reduces the toxicity of
BT, but also allows the administration of a higher dose, leading to better local control (Stur-
dza et al., 2016; Tanderup et al., 2016). Research also focuses on improving chemotherapy
treatment, by both deﬁning the best drug combination and treatment sequence (Haie-Meder
et al., 2010a; Vordermark, 2016).
EBRT for cervical cancer has been administered by three-dimensional (3D) conformal
radiotherapy in most centres since the turn of the 21st century. However, IMRT has gradually
become the preferred technique to administer EBRT for these patients, based on the following
clinical evidence. The ﬁelds included in this treatment are the cervical tumour, uterus,
parametria, part of the vagina (the amount depends on vaginal tumour extension) and
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pelvic lymph nodes +/- inguinal and or paraaortic lymph nodes when involved. The total
dose administered is between 45 and 50.4 Gray (Gy) in fractions of 1.8-2 Gy (Vordermark,
2016; Gandhi et al., 2013). Gandhi et al., (2013) compared toxicity and disease-free and
overall survival in a small randomised trial including 44 patients, between 3D conformal
radiotherapy and IMRT, both with concomitant cisplatin, for LACC. Pelvic radiotherapy
with or without extended ﬁelds, when indicated, was administered. Although there was
no signiﬁcant diﬀerence in terms of survival, there were notable diﬀerences in favour of the
IMRT arm for both acute and late digestive tract toxicity. There were 32% less grade 2 and
almost 23% less grade 3 acute gastrointestinal toxicities, and 36.4% less late gastrointestinal
toxicities in the IMRT arm (Gandhi et al., 2013). Another advantage of using IMRT for the
treatment of cervical cancer is the ability to administer a simultaneous integrated boost to
macroscopic lesions. The feasibility of this technique was presented in a study comparing
IMRT by helical tomotherapy with standard IMRT (Marnitz et al., 2011). The technique
was feasible for both IMRT techniques, administering a simultaneous integrated boost at a
dose of 2.12 Gy per fraction, 28 fractions, to the bilateral parametria.
BT is an essential treatment in LACC, as has been shown by an analysis of the Surveil-
lance, Epidemiology, and End Results (SEER) database of patients treated for stage IB2-IVA
carcinoma of the cervix (Han et al., 2013). The multivariate analysis of the cohort matched
by propensity-score demonstrated that treatment with EBRT + BT independently induced
higher cause speciﬁc survival and overall survival, with a hazard ratio (HR) of 0.65 (95%
conﬁdence interval (CI): 0.57-0.71) and 0.66 (95% CI: 0.60-0.74), respectively, when com-
pared with EBRT alone. Interestingly, the year when Medicare insurance began covering
IMRT in each SEER region, there was a clear decrease in the use of BT. While, as mentioned
earlier, IMRT allows better sparing of organs at risk (OAR) than 3D conformal EBRT, it
does not allow the administration of such high doses to the tumour as BT while avoiding
OAR. This was shown in a study comparing magnetic resonance imaging (MRI) based IGBT
with IMRT and intensity modulated proton radiotherapy (IMPT) (Georg et al., 2008). This
study was particularly interesting, as it included IMPT, which has a steep dose gradient, al-
lowing for better target coverage while sparing OAR. However, the study showed that IGBT
was superior not only to IMRT, but also to IMPT, with better coverage of the gross tumor
volume (GTV) (Figure 1.1). High dose rate BT treatments after EBRT for cervical cancer
are most often administered in 3-5 fractions of 5-7 Gy per fraction (Vordermark, 2016).
Classic two-dimensional (2D) BT treatments were prescribed to point A, as designated by
the Manchester System (Vordermark, 2016). The drawback of this system is that it did not
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Figure 1.1: Isodose curves for IGBT, IMRT and IMPT. Abbreviations: HR-CTV: High risk CTV; IR-CTV: Intermediate risk
CTV; HR-PTV: High risk planning treatment volume; IR-PTV: Intermediate risk planning treatment volume. Reprinted from
D. Georg et al. Image-guided radiotherapy for cervix cancer: high-tech external beam therapy versus high-tech
brachytherapy. Int. J. Radiation Oncology Biol. Phys. 71.4 (2008), pp. 12721278, c© 2008, with permission from Elsevier.
take into account anatomic variations between patients nor the extension of the tumour. The
need to determine more accurately the coverage of the tumour, as well as the dose received by
the OAR, led to the development of 3D IGBT, either computed tomography (CT)-based, or
ideally MRI-based. Much eﬀort has been made by the Groupe Européen de Curiethérapie 
European Society for Radiotherapy and Oncology (Gyn GEC-ESTRO) to optimise IGBT and
develop guidelines for its implementation. The language to be used for IGBT was introduced
in Gyn GEC-ESTRO guidelines published in 2005, where the terminology to be applied in
this technique was clearly deﬁned (Haie-Meder et al., 2005). Thus, GTV, high risk CTV
(HR-CTV) and intermediate risk CTV (IR-CTV) delineation deﬁnitions were established.
The aim of these guidelines was to improve contouring accuracy of target volumes in IGBT
because it aﬀects the treatment plan, as does contouring of OAR. For this, the importance
of the use of MRI to improve target volume (TV) deﬁnition, especially for the GTV, was
stressed. The second part of the Gyn GEC-ESTRO guidelines focused on dose volume
histogram (DVH) values for TV as well as constraints for OAR (Pötter et al., 2006).
An intErnational study on MRI guided BRachytherapy in locally Advaced CErvical can-
cer (EMBRACE)1 began in 2008 to prospectively evaluate observationally the clinical results
of the use of MRI-based IGBT in several centres following Gyn GEC-ESTRO contouring and
reporting guidelines. While we await the outcome of this trial, which closed to inclusions at
1http://www.embracestudy.dk
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the end of 2015, the retroEMBRACE2 data is available (Sturdza et al., 2016). RetroEM-
BRACE is the cohort of 731 patients for analysis which received IGBT in the monoinstitu-
tional setting within 12 centres before they entered EMBRACE. With a median follow-up
of 43 months, 5 year actuarial local control was 89% with a pelvic control of 84%, an overall
survival of 65% and a cancer speciﬁc survival of 73%. The actuarial 5 year morbidity was 5%
for bladder and vagina and 7% for the gastrointestinal tract (Sturdza et al., 2016). Though
retrospective, and only 81% had MRI-based IGBT, these favourable results will hopefully
be reconﬁrmed or even improved with the EMBRACE data.
An important aspect of standard treatment for LACC is keeping the overall treatment
time between the beginning of chemoradiation and the end of BT under 55 days (Haie-Meder
et al., 2010a). This aspect was evaluated in a subcohort of retroEMBRACE treated with
MRI-based image guided radiotherapy (IGRT) (Tanderup et al., 2016). In these 488 patients
not only prolonged overall treatment time (p-value = 0.004, HR = 1.023 per day), but also
larger HR-CTV volume (p-value = 0.004, HR = 1.017 per cm3) were found to associate with
lower local control rates. This study recommended adding to the dose which covers 90% of
the HR-CTV of 85 Gy a dose of 5 Gy to reach equivalent 3 year local control per additional
week of overall treatment time (>49 days median overall treatment time) or per 10 cm3 of
increased HR-CTV volume (Tanderup et al., 2016).
Recently, data has begun to become available for the use of stereotactic body radia-
tion therapy (SBRT) in gynaecological cancers. It is quite useful to treat node metastases,
whether pelvic and/or para-aortic, as well as for salvage treatment of extra-nodal recurrences
in the pelvis. SBRT's most prominent role in gynaecological cancer is nodal boosting, as
reported in a recent systematic review (Figure 1.2) (Mendez et al., 2017; Choi et al., 2009).
SBRT for nodal boosting in 183 patients from 6 studies yielded a combined local control rate
of 83% (median follow up range: 4-20 months) with under 5% of grade 3-4 toxicity of the
gastrointestinal tract and only one patient with grade 3 genitourinary toxicity. When used
as salvage treatment for pelvic recurrences in 10 studies, 73 patients in total, local control
reported for 57 of those patients was 86% with a range of median follow up of 4-20 months. A
less employed SBRT approach in cervical cancer is either radical treatment or postoperative.
Seven studies present data of SBRT as a radical treatment in LACC, reporting results of 34
patients. With a median follow up of 6-22 months, they found a combined local control of
91%. Only 2 patients suﬀered grade 3 or 4 gastrointestinal side eﬀects (Mendez et al., 2017).
A ﬁnal aspect to be considered when discussing radical radiochemotherapy treatment for
2http://www.retroembrace.com
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Figure 1.2: SBRT treatment plan for CyberKnife (39 Gy in three 13 Gy fractions). The GTV was the macroscopic para-
aortic lymph node mass on CT scan (in red). The dose prescription was to the 81% isodose line of the maximum dose to
cover the GTV + 2-mm margin (light blue, long arrow). The 30% isodose line is in blue (short arrow). Reprinted from C.
Choi et al. Image-guided stereotactic body radiation therapy in patients with isolated para-aortic lymph node
metastases from uterine cervical and corpus cancer. International Journal of Radiation Oncology Biology Physics 74
(2009), pp. 147153 c© 2009, with permission from Elsevier.
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LACC is how to estimate the total dose (including posterior BT) to be received by surround-
ing OAR when boosting macroscopic pelvic lymph nodes with IMRT before BT. To this end,
a recent study developed the concept of coverage probability (Ramlov et al., 2017). Coverage
probability planning informs better of the spatial uncertainties in treatment administration,
allowing for less stringent planning goals around the planning treatment volume (PTV),
reducing the dose near OARs while still accurately boosting the macroscopic lymph nodes.
The simultaneous integrated boost dose, to be administered to the macroscopically involved
nodes during the administration of 45 Gy in 25 fractions to the pelvic lymph nodes, was 55-
57.5 Gy depending on the prospective BT dose contribution. They reviewed 25 patients with
47 boosted lymph nodes. Boosted lymph nodes were contoured on cone-beam CT (CBCT),
and the accumulated dose (EBRT + BT) they received was >57 Gy in 98% of the treated
nodes (GTV nodes as contoured on the CBCT). When planning was performed per the cov-
erage probability technique, the volume of the OAR (body, bowel and bones) receiving 50
Gy was signiﬁcantly lower than when planning classically per PTV node coverage (Ramlov
et al., 2017).
Considering the solid evidence in favour of concomitant chemoradiation, especially using
cisplatin, as previously mentioned, improvements to this scheme are under investigation.
Eﬀorts in this direction have consisted of either an intensiﬁed chemotherapy dose approach
to chemoradiation, complementary sequential chemotherapy, or both (Vordermark, 2016).
Another approach, the use of targeted therapy, was contemplated as an ulterior application
of the results obtained in the European multicentre study within which this thesis was
conducted.
A study intensifying both chemoradiotherapy and adding sequential chemotherapy com-
pared standard cisplatin-based chemoradiation to cisplatin-gemcitabine chemoradiation fol-
lowed by two adjuvant cycles of cisplatin-gemcitabine (Dueñas-González et al., 2011). Even
though the experimental arm showed higher 3 year progression free survival, by almost 10%,
and higher overall survival, there was almost 3 times more grade 3/4 haematologic toxicity in
the cisplatin-gemcitabine arm. A main issue in this trial is that it was run, for the most part,
in developing countries. The radiotherapy treatments were not optimal, as neither IMRT
(possibly even 2D EBRT was used for some patients, as ﬁeld borders were speciﬁed in the
supplement) nor IGBT were used. Furthermore, no centralised quality assurance was per-
formed. This puts the results in question, thus this scheme is not widely used (Vordermark,
2016).
As for the use of targeted therapy in LACC, vascular endothelial growth factor targeting
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with bevacizumab has been included in clinical trials within a chemoradiotherapy schedule.
The RTOG 0417 trial used a cisplatin-bevacizumab combination concomitantly with stan-
dard EBRT, followed by BT (Schefter et al., 2012). This combination proved to be safe,
and when looking at the 3-year overall survival in this trial, and the chemoradiation arm
of RTOG 90-01, results when adding bevacizumab were 81.3% vs. 76.8% (Schefter et al.,
2014).
Another direction under study is neoadjuvant chemotherapy in LACC. A systematic
review performed in 2003 including a meta-analysis of individual patient data found a
very signiﬁcant decrease in the risk of death with neoadjuvant chemotherapy before surgery
compared with radiotherapy alone (Neoadjuvant Chemotherapy for Cervical Cancer Meta-
analysis Collaboration, 2003). However, it was not compared with the current standard of
care, which is chemoradiation, and the GOG 141 was negative, thus no improvement was
shown with vincristine-cisplatin neoadjuvant chemotherapy followed by surgery in bulky
stage IB cervical cancer. Hence, neoadjuvant chemotherapy has not been broadly adopted
in LACC (Haie-Meder et al., 2010a). Results from the 2003 meta-analysis did provide ra-
tionale for the phase III EORTC 55994 trial which randomises patients with stage IB or
II cervical cancer to either neoadjuvant chemotherapy followed by surgery or chemoradio-
therapy. The results are awaited for 2019. A ﬁnal remark with respect to this subject is
based on a recent review from a Brazilian team (de Azevedo et al., 2016). Considering
that LACC is much more prevalent in developing countries, many of which have limited
access to radiation therapy, they decided to revise the current evidence available concerning
neoadjuvant chemotherapy in this setting. Their review of 7 pertinent trials concluded that
upfront neoadjuvant chemotherapy may be an option for those patients which have a lower
risk of progression, especially in the context of countries with less radiotherapy availability
(de Azevedo et al., 2016).
1.2 Speciﬁc context (RAIDs)
This thesis was performed within the frame of the European multicentre study Rational
molecular Assessments and Innovative Drug Selection (RAIDs) in Advanced Stage Cervical
Cancer, funded by the European Commission (Seventh Framework Programme) (Consortium
RAIDs, 2017). RAIDs integrated genomic studies and biochemical, molecular, virological
and cellular biology investigations on cervical cancer cells and tissues. Academic clinical
centres, small-medium enterprises, and academic and translational research platforms par-
15
Radiotherapy quality control in cervical cancer
ticipated in this project (Figure 1.3). The 22 clinical centres were fromWestern and Eastern
European countries (Table 1.2). As stated earlier, there is a large disparity between cer-
tain European regions in the incidence and mortality of cervical cancer, due to diﬀerences
in screening programme intensity and access to treatment, as well as the adequacy of the
treatment. Thus, one of RAIDs goals was to homogenise clinical management of cervical
cancer across the participating European centres.
Figure 1.3: European map showing participating RAIDs consortium centres.
The main objective of RAIDs was to deﬁne stratiﬁcation criteria for therapy by determin-
ing the tumour's molecular proﬁle (exome sequencing, reverse phase protein arrays (RPPA),
and integrative bioinformatics analyses). Tumour material was assessed within clinical and
translational trials before treatment and following therapeutic HPV vaccination.
Before performing these clinical and translational trials, treatment homogeneity needed
to be achieved among centres, particularly in radiochemotherapy, standard treatment for
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LACC. This was the aim of the task: Quality control for standard therapy, in particular
radiotherapy (RT) management in all clinical centres for which Gustave Roussy Cancer
Campus was the leader. This thesis was developed in partnership with this centre.
Considering the geographical diﬃculties involved and the limited funding, the best option
for training of the diﬀerent centres in radiotherapy treatment contouring for LACC was an
online workshop. This also allowed Gustave Roussy Cancer Campus to contribute to another
task within RAIDs: Training for young doctors and specialised health care physicians as well
as other health care actors.
FRANCE Institut Bergonié, Bordeaux
Institut Curie, Saint Cloud
Institut Curie, Paris
Institut Gustave Roussy, Villejuif
Institut de Cancérologie de Lorraine, Nancy
Centre Paul Strauss, Strasbourg
Centre Georges François Leclerc, Dijon
Institut de Cancérologie de l'Ouest, Nantes
Institut de Cancérologie de l'Ouest Paul Papin, Angers
Hôpital Européen Georges Pompidou, Paris
Institut du Cancer de Montpellier, Montpellier
Centre Antoine Lacassagne, Nice
SERBIA Institute of oncology of Vojvodina
NETHERLANDS Netherlands Cancer Institute  Antoni van Leeuwenhoek (NKI-AVL), Amsterdam
Amsterdam Medical Center (AMC), Amsterdam
GERMANY Hannover Medical School(MHH) Universitätsklinikum C.G. Carus_Klinik & Poliklinik für
Frauenheilkunde & Geburtshilfe, Dresden
ROMANIA Teo Health S.A., Brasov
Spitalul Clinic Municipal, Oradea
Institutul Regional de Oncologie, Lasi
Clinica Radioterapie, Timisoara
MOLDOVA Moldavian Oncological Institute, Chisinau
Table 1.2: List of participating RAIDs clinical centres.
1.3 Quality control in radiotherapy
Researchers began to realise the need for quality control for radiotherapy within clinical
trials at the end of the 1970's, with an initial aim to increase the number of patients included
in trials which were evaluable per protocol (Fairchild et al., 2013). At this time, the Radi-
ation Therapy Oncology Group (RTOG) implemented sample case reviews for radiotherapy
treatments (FitzGerald, 2012). Thus, in 1982, outcome results with respect to Radiation
Therapy Quality Assurance (RTQA) for Southwest Oncology Group Protocol 7628, ran-
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domising small cell lung cancer patients between multiagent chemotherapy and radiation
therapy with or without Bacillus Calmette-Guérin (BCG), were presented. They showed
that patient cases with major variations from protocol had signiﬁcantly worse survival (40
vs. 60 weeks, respectively; p-value = 0.002), a lower improvement of the response rate post-
induction chemotherapy (27 versus 48%, respectively; p-value = 0.05) and a higher rate of
chest recurrences (77 vs. 55%; p-value = 0.047) than protocol compliant patients (White
et al., 1982). These early results for the impact of quality assurance support the aﬃrma-
tion by Poortmans et al., (2005): the fact that patients included in clinical trials tend to
have better outcomes than others with similar characteristics, both in terms of therapeutic
results and less complications, with a better quality of life, can be due to patient selection
and more precise treatment, thanks to diagnostic and therapeutic quality assurance and
more attentiveness by the health care staﬀ in centres involved in clinical trials. Though
radiotherapy treatments which are not per protocol may waste time, eﬀort and money and
even harm patients, evidence shows that participating in RTQA programmes ameliorates
not only treatment delivery for trial patients, but also for oﬀ-trial patients (Weber et al.,
2011; Haworth et al., 2009).
The ﬁrst centre dedicated to quality assurance programmes was developed in the United
States: the Radiological Physics Center (RPC). It has received funds from the National
Cancer Institute (NCI) since the late 1960's to audit the dosimetries of participating centres
of NCI cooperative clinical trials, and as aforementioned, a decade later the RTOG created
radiotherapy sample case reviews. Also, the Quality Assurance Review Center (QARC) was
created, within the Radiation Oncology Committee for the original Cancer and Leukemia
Group B (CALGB) in 1976. The QARC elaborated a process to collect radiotherapy data
for review, allowing study investigators to perform both interventional and retrospective re-
views of radiotherapy treatments for all patients involved in clinical trials including this ra-
diotherapy review data. Early results from the CALGB RTQA procedures showed treatment
approaches from diﬀerent centres were inhomogeneous, manifesting a need for monitoring of
these treatments, especially when participating centres used techniques within the clinical
trial which were diﬀerent from their standard techniques (Fairchild et al., 2013). By the
1980's RTQA faced another challenge, due to the gradual implementation of 3D treatment
planning, thanks to a more generalised access to CT. This led to the introduction of bench-
marking exercises, allowing assessment of the radiotherapy equipment, the team and their
capabilities. These exercises gave RTQA facilities insight as to how patients were treated in
each participating centre (FitzGerald, 2012).
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In Europe the European Organisation for Research and Treatment of Cancer (EORTC)
RTQA programme was inaugurated in 1982 (Kouloulias, 2003). It was developed within the
Radiation Oncology Group (ROG), which established the ways and the principles of RTQA
within European clinical trials (Fairchild et al., 2012b).
To elaborate on the concept of RTQA, it allows for close observation and assessment
of how radiotherapy techniques are performed within clinical trials, but also in an institu-
tion when used for internal quality assurance. Radiotherapy treatment preparation involves
several professionals other than the treating physician, such as the radiation therapy tech-
nologist who scans the patient (in 3D EBRT), medical residents, physicists and lastly the
radiation therapy technologist who administers the treatment. Consequently, human error
and/or software faults may ensue during any of the steps of the process. RTQA has been
deﬁned as the procedures which guarantee consistency of the radiotherapy prescription and
the safe application of the prescription through the treatment plan by administering the
correct dose to the TV while sparing at best the OAR, minimising the radiation exposure
of the personnel and providing adequate patient follow up during treatment as well as after-
wards, to assess outcomes (Institute of Radiation Hygiene and World Heath Organization,
1988). RTQA has three pillars, the structure in which the treatment is delivered, the process
of treatment preparation and the outcome for the patients (van der Schueren et al., 1993).
The goals of RTQA are to deﬁne acceptable protocol deviations, identify possible reasons
for larger deviations, and devising mechanisms to correct and prevent them, so as to de-
crease variability and uncertainties encountered during the steps of treatment planning and
administration (Weber et al., 2011).
Technological innovations inducing advanced radiotherapy techniques have brought about
a growing interest in RTQA programmes. The application of novel, more complex, radiother-
apy treatment techniques increase the possibility of issues with the quality of the treatment
delivered (Spry et al., 2008). Due to this, the cost of conducting clinical trials and the higher
number of patients accrued, a larger demand has arisen for rigorous RTQA programmes
which may ensure patients will be treated optimally, per protocol. In current times, only
studies which are well conducted with a well documented RTQA programme have credi-
bility. This is the only way to produce robust, deﬁnitive results which may be generalised
and result in a change of clinical practice. Also of utmost importance is the fact that many
modern trials are multidisciplinary and international, thus intrinsically less concordant and
homogeneous across participating centres (Weber et al., 2011).
RTQA programmes within multicentre trials should:
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• Clarify any protocol ambiguities with possible impact on treatment delivery.
• Train participating centres in radiotherapy aspects of the trial guidelines.
• Ensure treatment homogenisation between centres.
• Warrant sites satisfy the needed technical and staﬀ requirements.
• Guarantee data integrity as well as its accuracy.
• Estimate variability between patients and institutions.
• Identify and correct any ﬂaws in the design of the study (Weber et al., 2011).
RTQA programmes have come a long way since their initial conception in the 1960's-70's.
They have not only kept up with cutting edge technological advances in the ﬁeld of radio-
therapy (and helped ease their implementation safely in departments within clinical trials),
but have also integrated these and other advances in the RTQA process itself, allowing for
a more streamlined, user-friendly RTQA programme. Initial eﬀorts consisted of site visits,
assessments of the personnel and infrastructure of participating centres, mechanical and dosi-
metric evaluations of treatment units, patient chart and portal imaging reviews, dosimetry
audits by mailed in thermoluminescent dosimeters and even the development of radiobiolog-
ical models to assess inter-institutional diﬀerences (Poortmans et al., 2005; Fairchild et al.,
2012b). These assessments brought about the creation of the dummy run. This initially
consisted of treating a dummy patient (an anatomical phantom) per protocol guidelines and
was ﬁrst used in the EORTC RTQA programme in the EORTC 22791 protocol, studying
conventional vs. bifractional radiotherapy in cancers of the oropharynx. They found an
accurate delivered dose in the central axis in all cases, but many diﬀerences in treatment
planning with approximately one third of the cases with inadequate TVs (either too small
or too large). Thus, the EORTC RTQA programme implemented this dummy run to be
performed before opening trial centres to detect any possible deviations and correct any
misinterpretation of the trial guidelines prior to patient inclusion. A couple years later, they
decided to include case reviews of patients treated on the trial, individual case review (ICR),
to detect random errors. These ICR consisted of a review of parameters of the patient, the
tumour and the treatment to assess whether the patient had been treated per protocol guide-
lines (Poortmans et al., 2005). Several reasons which may be responsible for non-compliance
with dummy run guidelines have been identiﬁed (Table 1.3) (Fairchild et al., 2012a).
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Table 1.3: Proposed reasons for non-adherence to dummy run guidelines. Reprinted from A. Fairchild et al. Do results of
the EORTC dummy run predict quality of radiotherapy delivered within multicentre clinical trials? European
Journal of Cancer 48 (2012), pp. 32323239, c© 2012, with permission from Elsevier.
A landmark EORTC trial including an exhaustive RTQA programme for that time was
the EORTC 22922/10925 study. Four steps were within this speciﬁc RTQA programme:
1. Veriﬁcation of the consistency of the data at the EORTC Data Centre by performing
a double data entry procedure in the centralised database.
2. Completion of a dummy run.
3. Early reviewing of patient eligibility and treatment compliance.
4. Mailing of thermoluminescent dosimeters to evaluate electron dosimetry.
When evaluating the results of the dummy run, signiﬁcant deviations from protocol were
found for treatment setup and prescription, causing a signiﬁcant variation of the prescribed
dose to the internal mammary chain - medial supraclavicular fossa in 10% of the cases for
the control group, and in 21% for the nodal-irradiation group. These deviations would
likely aﬀect the survival beneﬁt this study was powered to detect, which would decrease
to a true 3.8% beneﬁt as opposed to the initially calculated 5% beneﬁt to be found with
nodal-irradiation. Thus, this could potentially lead to a false negative result of the study.
Looking on the bright side, since the dummy run was performed early in the trial, this allowed
recommendations to be made to centres based on the results to avoid the deviations in future
patients. Also, the protocol was amended based on these recommendations (Poortmans et
al., 2001). Ultimately, 10 year overall survival results proved, in eﬀect, to be marginally, but
not signiﬁcantly better in the nodal-irradiation arm (82.3%) vs. 80.7% in the control arm
(HR for death with nodal irradiation, 0.87; 95% CI, 0.76 to 1.00; p-value = 0.06) (Poortmans
et al., 2015).
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In 2006 the EORTC RTQA platform established ﬁve levels of RTQA requirements for
centres participating in EORTC trials Table 1.4 . Level 1 includes general strategies to en-
sure minimal acceptable quality radiotherapy to be administered in all participating centres.
Further levels are protocol-speciﬁc credentialing, to be adapted depending on the aim of the
trial and the technological complexity of the radiotherapy techniques (Weber et al., 2011).
Table 1.4: EORTC levels of RTQA. Reprinted from D. C. Weber et al. Quality assurance for prospective EORTC
radiation oncology trials: The challenges of advanced technology in a multicenter international setting. 2011,
c© 2011, with permission from Elsevier.
RTQA centres guarantee homogeneous radiotherapy treatment delivery between sites in-
cluded in clinical trials, ameliorating protocol compliance, minimising deviations from proto-
col, revealing systematic errors during the clinical treatment process and detecting misinter-
pretations or misunderstandings of trial protocols. RTQA plays an important role in clinical
trials, even when radiotherapy does not constitute the main study endpoint, although its
intensity may vary depending on the weight radiotherapy has on the study question. Thus,
all RTQA programmes need to pursue treatment homogeneity to obtain a trial compliant in-
terpretable population without hindering patient accrual (FitzGerald, 2012). Unfortunately,
some RTQA programmes demanded many human, technical and monetary resources, ul-
timately hampering trial accrual. This, and the fear of losing participating centres which
are not compliant with the RTQA process, has caused reluctancy from study coordinators,
participating centres and/or cooperative groups to participate in obligatory RTQA creden-
tialing (Weber et al., 2012). Another issue is that results of trials with excellent RTQA may
not correspond with results from standard- RTQA used in clinical practice (Bekelman et al.,
2012). These issues highlight the need for a rational design of RTQA programmes, which
should be well adapted to the requirements of each particular clinical trial.
Once the key role of RTQA within clinical trials was clearly established, early on, RTQA
guidelines were developed by societies such as European Society for Radiotherapy & Oncol-
ogy (ESTRO) (Thwaitesa et al., 1995). Nowadays speciﬁc RTQA procedures are available,
the main ones are summarised in a table including all centres in the Global Clinical Trials
RTQA Harmonization Group (GHG) (Table 1.5). They allow for a quite rigorous qual-
ity assurance process, but unfortunately not all centres use the same nomenclature, which
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complicates the intercomparison of these procedures. To remedy this situation, the GHG
has made an important eﬀort to reach a common language, speciﬁed in Table 1.6, where
they were able to produce a homogeneous set of 10 out of the 27 RTQA procedures analysed
from the GHG centres (Melidis et al., 2014). Even templates, which can be adapted to
trial situations, have been written to facilitate the preparation of RTQA programmes within
clinical trials (Nilsson et al., 2014).
A ﬁnal and quite necessary step to facilitate the logistics of RTQA procedures was the
development of quality control platforms for digital data transfer (Fairchild et al., 2012b).
These platforms have considerably evolved over the past two decades, leading to real time
quality control servers where participating centres may upload their data, allowing it to be
reviewed by the central reviewers. As previously mentioned, RTQA requirements have much
evolved due to the complexity of modern radiotherapy techniques, calling for exponentially
increasing amounts of data which need to be received in an accurate and timely fashion to
allow interpretation by central RTQA reviewers. A digital data facility allows prospective
collection of RTQA data with real-time review of ICR, facilitating early detection of trial de-
viations, leading to a prompt implementation of corrective actions or protocol amendments if
necessary. Another notable advantage is the possibility of performing real-time case reviews
of contouring and dosimetry procedures before a trial patient is treated, thus ensuring treat-
ments are performed per protocol (Fairchild et al., 2012b; Willett et al., 2012). Digital data
transfer facilities also reduce RTQA costs by eliminating mail and storage costs, site visits
and reducing review time (digital data is quicker to revise than hard copies). The EORTC's
response to this need is the Visualization and Organization of Data for Cancer Analysis
(VODCA) programme. It includes digital radiotherapy imaging, treatment planning and
veriﬁcation data for review. The VODCA platform provides quick, thorough, prospective
patient reviewing for international multicentre clinical trials, and can assist multinational
or intergroup collaborations. Currently, a team is necessary for collection and veriﬁcation
of the data, followed by its review. This is especially needed since collecting data through
digital data transfer quality control platforms often deals with the issue of the homogeneity
of the nomenclature used for region of interest (ROI), DVH, toxicity, dose and volume units.
In an endeavour to standardise this nomenclature, the American Association of Physicists
in Medicine (AAPM) has launched the task group 263 (Mayo et al., 2015). This is a barrier
which will need to be surpassed to advance towards future directions such as the integration
of automatic review software, which would much relieve central reviewers of this systematic
part of RTQA, allowing them to focus on other aspects. Another very promising future in-
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Table 1.5: RTQA procedures used by the members of the GHG steering committee. Reprinted from C. Melidis et al. Global
Harmonization of Quality Assurance Naming Conventions in Radiation Therapy Clinical Trials. International
Journal of Radiation Oncology Biology Physics 90.5 (2014), pp. 12421249, c© 2014, with permission from Elsevier.
novation may be its integration with the platforms of headquarter imaging and translational
research units (Fairchild et al., 2012b).
Lastly, study reviews and a meta-analysis have found an association between RTQA and
clinical patient outcomes. A review including nine trials (Weber et al., 2012) presented
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Table 1.6: Procedures described by the naming conventions of RTQA procedures agreed upon by the members of the GHG
steering committee. Abbreviations as in Table 1.5. Reprinted from C. Melidis et al. Global Harmonization of Quality
Assurance Naming Conventions in Radiation Therapy Clinical Trials. International Journal of Radiation Oncology
Biology Physics 90.5 (2014), pp. 12421249, c© 2014, with permission from Elsevier.
the results of the RTQA programme with the corresponding patient outcome for six trials
(Table 1.7). They found that RTQA deviations aﬀected the primary study aim in 62.5% of
the nine reviewed trials. Fairchild et al., (2013) have reviewed the evidence supporting the
correlation of RT quality with clinical outcomes in seventeen multicentre clinical trials and
one Patterns of Care Study (Fairchild et al., 2013). Seven showed signiﬁcantly higher failure
rates after inadequate versus adequate RT. Five of nine and two of ﬁve studies reported
signiﬁcantly worse overall and progression-free survival after poor quality RT, respectively.
They conclude that protocol-compliant RT may decrease failure rates and increase overall
survival and probably aﬀects the ability to answer the central trial question. A meta-analysis
performed earlier the same year, including eight cooperative group trials, reached a similar
conclusion, as radiotherapy protocol deviations were signiﬁcantly associated with higher risks
of failure of the treatment and overall mortality (Ohri et al., 2013).
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Table 1.7: Correlation between RTQA programmes and patient outcomes in 6 prospective clinical trials. Reprinted from D. C.
Weber et al. QA makes a clinical trial stronger: Evidence-based medicine in radiation therapy. Radiotherapy and
Oncology 105.1 (2012), pp. 48, c© 2012, with permission from Elsevier.
1.3.1 The importance of adequate delineation of regions of interest
Delineation of treatment plans is key in radiotherapy treatment. Proper delineation of
both TV and OAR allows for an optimal oncological treatment along with more precise
knowledge of the dose administered to the surrounding healthy tissue. Due to this fact, sev-
eral studies have evaluated both the interobserver and the intraobserver variability between
contours (Rasch et al., 1999; Petric et al., 2008; van Mourik et al., 2010; Petri£ et al., 2013).
Since the 1990's studies presenting results from RTQA programmes within multicentre
trials have found that variability in the delineation of TV was the factor with the greatest
impact on RTQA deviations (Kouloulias et al., 2004). And not only is this the case for
TV deﬁnition. An analysis of the impact of variations in rectal contouring, when consider-
ing interobserver variability, within a multicentre trial on prostate cancer showed that even
when most observers agreed on rectal deﬁnition, contouring was still an important source of
uncertainty (Foppiano et al., 2003). To evaluate whether the use of protocol guidelines for
contouring decreased interobserver variations, a contouring study for postoperative radio-
therapy in lung cancer was performed within the international multicentre Lung Adjuvant
Radiotherapy Trial (LungART) (Spoelstra et al., 2010). Ten physicians sent in their routine
clinical target volume (CTV) (per their routine clinical practice) and six sent in routine and
protocol CTV for two cases. There was a variation of up to three times between physicians,
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which decreased signiﬁcantly with the use of the LungART protocol (Spoelstra et al., 2010).
These results support the need to perform obligatory dummy runs within multicentre trials
in the 3D conformal radiotherapy era.
To highlight this role of ROI delineation within RTQA, pertinent results were found in a
study performed within the RTOG which performed a detailed review of radiotherapy guide-
line compliance within recent RTOG digestive tract trials. Components of the radiotherapy
process were scored and ultimately deemed as according to per-protocol, variation acceptable
or deviation unacceptable. When scoring anal cancer trials (three phase III trials: RTOG
9405, RTOG 9704, and RTOG 9811 and an IMRT trial: RTOG 0529), most unacceptable
deviations were due either to errors in ﬁeld design or in contouring of the GTV, and very
rarely due to errors in dose or fractionation (Willett et al., 2012).
1.3.2 Application in cervical cancer
Speciﬁcally, in the ﬁeld of cervical cancer, with the implementation of modern day radio-
therapy techniques, such as IMRT and IGBT, RTQA acquires an even higher signiﬁcance.
In recent years, the use of these advances in EBRT, and BT (especially IGBT), have yielded
excellent 3 year local control rates (92% in tumours >5 cm and 98% in tumours 2-5 cm)
(Pötter et al., 2011). The achievement of these rates was by the use of Gyn GEC-ESTRO rec-
ommendations for contouring of the HR-CTV and for evaluation of dose volume constraints
for OAR (Haie-Meder et al., 2005).
Results for RTQA in LACC cervical cancer were presented for the Gynecologic Oncology
Group (GOG) protocol 165 in an abstract. They compared retrospectively high dose rate
(HDR) BT treatments administered in centres that were fully credentialed before including
patients in the trial with those that were administered in non-credentialed centres. All HDR
BT treatments delivered in credentialed centres had no major protocol deviations, while of
those delivered in non-credentialed centres only 81% had no major deviations (Lowenstein
et al., 2002).
One of the ﬁrst fully-published trials detailing RTQA in cervical cancer was for early
stages (Toita et al., 2009). This Japanese multicentre prospective trial (JAROG0401/JROSG04-
2) evaluated the outcomes and side eﬀects of exclusive radiotherapy, including HDR BT
administration. All the treatment plans of the 60 patients included in this trial had an
ICR. Modern radiotherapy techniques such as IMRT and IGBT were not used in these pa-
tients, and EBRT ﬁelds were evaluated per 2D bony landmarks. The data required for
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the ICR were baseline MRI, EBRT treatment charts, digitally reconstructed radiographs or
simulation ﬁlms, electronic portal imaging device dose distributions or veriﬁcation portal
ﬁlms, HDR BT treatment charts, ﬁlms and isodose distributions for all applications. Of
all deviations, the most frequent one was non-compliance for point A deﬁnition, followed
by diﬀerences between simulation and veriﬁcation ﬁlms of over 5 mm. In general there was
good protocol compliance within this study, although the lesser complexity of the techniques
most probably favoured these results (Toita et al., 2009).
More recently, more rigorous RTQA has been performed in the ﬁeld of cervical cancer,
within the EMBRACE and the Induction Chemotherapy Plus Chemoradiation as First Line
Treatment for Locally Advanced Cervical Cancer (INTERLACE) trials (ClinicalTrials.gov
NCT01566240, 2012). The RTQA in these trials has evolved in response to the more com-
plex radiotherapy techniques included in these studies, such as IMRT (optionally) or IGBT
(optional for the latter).
The importance of adequate delineation of regions of interest in cervical cancer
Little has been published concerning uncertainty in EBRT TV contouring for cervical
cancer (Weiss et al., 2003; Wu et al., 2005). In one study, seven clinicians (ﬁve radiation
oncologists and two gynaecologists) contoured all CTV for three cervical cancer patients.
The inclusion of the adequate regions in each CTV was fairly consistent amongst observers.
However, there was ﬂagrant interobserver variability. They concluded that CTV delineation
seemed to inﬂuence the accuracy of treatment delivery more than other factors, such as
patient set-up or organ motion (Weiss et al., 2003).
Such evidence led to a quite exhaustive RTQA programme performed within the INTER-
LACE trial (Eminowicz et al., 2016a; Eminowicz and Mccormack, 2015; Eminowicz et al.,
2016b). Although none of the participating trial centres were using IMRT at the time, in the
perspective of implementing this technique for LACC treatments in participating centres, a
detailed atlas was developed to aid delineation (Eminowicz et al., 2016a). Their aim was to
reduce interobserver contouring variability, as it has been shown that guideline use reduces
this variability in other tumour types. The RTQA team performed a literature search for
guidelines for ROI determination in cervical cancer, and after identiﬁcation of seven papers
they found eleven areas of variation. The bowel, femur, vagina, parametria, nodal borders
including cranially and caudally, para-aortic nodes, and the margin around macroscopically
enlarged nodes were within these areas. This information was used to create consensus con-
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touring guidelines for the INTERLACE protocol, and the proportion of protocol-compliant
contours before and after the implementation of these guidelines was analysed. Four ROI
were analysed to this end, primary CTV, CTV-nodes, bladder and rectum. The average
proportion of protocol compliant contours increased by 1.8, then to 2.7 after atlas imple-
mentation (diﬀerence of 0.9; 95% CI, 0.3-1.5; p-value = 0.003) , clearly reducing interobserver
diﬀerences in contouring.
Considering the excellent, previously mentioned, local control results obtained with
IGBT, this breakthrough in treatment for cervical cancer has prompted several studies,
culminating in the EMBRACE initiative. Some of these studies have found that detailed
guidelines and training in contouring can improve consistency in GTV and CTV deﬁnition
in IGBT (Petric et al., 2008; Dimopoulos et al., 2009)
However, little data have been published on speciﬁc IGBT RTQA. To date, the most
representative data comes from the EMBRACE trial (Kirisits et al., 2015). In this study
there were no speciﬁcations for BT dose prescription, centres were to treat according to their
institutional protocols (for dose, fractionation, dose rate and technique). Considering that
centres had diﬀerent BT techniques (applicator types, type of imaging and planning used),
they did not all receive the same clinical case to perform the dummy run, rather they were
asked to send in two of their own cases which met certain clinical requirements. Only BT
contouring of TV, dose and volume reporting was required to be per Gyn GEC-ESTRO
recommendations. EBRT was administered per EMBRACE guidelines for TV deﬁnition,
planning, dose and fractionation, and overall treatment time. Nine of the 30 participating
centres were considered as experienced in IGBT. For both EBRT and BT techniques, the
largest variations were due to contouring. As expected, there were less protocol deviations
for experienced centres with respect to those with less experience in IGBT (Kirisits et al.,
2015).
All of this evidence supported the performance of a dummy run within the RAIDs trial, to
ensure that the patients identiﬁed as non-responders to standard chemoradiation treatment
were in eﬀect resistant to treatment, and had not simply received inadequate chemoradiation.
This way correctly identiﬁed non-responders could be correlated with potentially treatable
genomic, proteomic, biochemical, molecular, virological or cellular biology alterations.
As the RAIDs trial included very geographically distant countries, a practical approach
was to perform this dummy run online. Mcenery et al., (1995) found that online educa-
tional tools oﬀer the possibility to achieve interactive medical instruction for geographically
dispersed students. However, especially in the medical ﬁeld, it can sometimes be diﬃcult
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for both the faculty and health care professionals to use the technology eﬃciently and eﬀec-
tively. Experience within this ﬁeld seems to suggest that an optimal model of delivery could
include both face-to-face and e-learning components, deemed as blended learning (Sharpe
et al., 2006).
Flexibility is a basic consideration within e-learning programmes, especially within highly
demanding professions such as those found in the health-care setting. A systematic review
has found that this is often manifested as learner control, which demands diﬀerent entry
points and learning trajectories during a course, with self-regulation of task management
and adaptation to local and personal circumstances (Booth et al., 2009).
An important issue in e-learning is student outcome evaluation. Very few reports include
objective internal testing to validate web-based learning tools as a primary outcome (Kronz
et al., 2000; Erickson et al., 2003; Ridgway et al., 2007).
The purpose of this study is to validate the methodology of this new concept of online
delineation workshop (ODW) in LACC within the European multicentre prospective study
RAIDs, by reviewing the participant contours in the diﬀerent stages as well as their personal
perception of the knowledge acquired.
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2.1 Primary endpoints:
1. Interobserver validation of the online delineation workshop (ODW) in locally advanced
cervical cancer (LACC) by using qualitative and quantitative assessments of the im-
provement of the clinician contours between clinicians (interobserver variability).
2. Intraobserver validation of the ODW in LACC by assessing qualitatively and quan-
titatively the improvement of the clinician contours for each clinician (intraobserver
variability).
2.2 Secondary endpoints:
1. Evaluation of the teaching methodology of the online contouring workshop as reﬂected
by the participant satisfaction questionnaires.
2. Analysis of clinician contouring on magnetic resonance imaging (MRI) for European
centres which use MRI for brachytherapy planning versus those which do not.
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3.1 Assessment of locally advanced cervical cancer radio-
therapy treatments in RAIDs centres
The ﬁrst step was to assess general practice in participating clinical Rational molecular
Assessments and Innovative Drug Selection (RAIDs) centres. For this purpose, a general
questionnaire about locally advanced cervical cancer (LACC) radiotherapy was prepared and
sent to RAIDs centres (Table 3.1). This questionnaire allowed for a basic baseline evaluation
of their local treatment protocols before their enrollment in the online delineation workshop
(ODW). The RAIDs trial was observational and collected diﬀerent treatments administered
to patients through the electronic case report forms (eCRFs), but did not require following
any particular treatment protocol, other than radiotherapy contouring guidelines speciﬁed
in the ODW both presented interactively and supplied in writing. Most interestingly, this
questionnaire allowed the evaluation of the experience of the centres in the treatment of
cervical cancer, as well as the techniques used for external beam radiotherapy (EBRT) and
brachytherapy (BT).
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Which best describes your institution?
A) Private centre
B) Academic centre
C) Public centre
How many cervix patients do you approximately treat per year with deﬁnitive radiotherapy
including external beam therapy, chemotherapy and brachytherapy?
A) 0-50
B) 50-100
C) ≥ 100
Which cervix cancer patients do you treat with deﬁnitive radio(chemotherapy)?
A) Patients with positive pelvic and/or paraaortic lymph nodes
B) Patients with positive paraaortic lymph nodes
C) If distant metastasis is excluded I treat all patients with tumour stages I-Iva
D) Patients with negative lymph nodes if local tumour stage is IIb or greater
Which applicator do you use?
A) Tandem/ring
B) Ovoids
C) Mould
D) Tandem/cylinder
E) Interstitial needles
Do you use interstitial application techniques for brachytherapy?
A) Yes
B) No
Which dose rate do you use?
A) high dose rate (HDR)
B) pulsed dose rate (PDR)
C) low dose rate (LDR)
Which kind of imaging do you perform with the applicator in place at the time of brachyther-
apy?
A) X-ray
B) C-arm cone-beam CT (CBCT)
C) computed tomography (CT)
D) magnetic resonance imaging (MRI)
E) ultrasound (US)
In case you are not doing 3D image based dose planning: when do you plan to start?
A) in the next 6 months
B) within one year
C) within 3 years
D) I don't know / don't plan to
To which volume/point do you prescribe brachytherapy dose?
A) Point A
B) high risk CTV (HR-CTV)
C) intermediate risk CTV (IR-CTV)
D) Other
Which total EQD2 dose do you prescribe to the target volume/point indicated above?
A) <65 Gy
B) 65-74 Gy
C) 75-79 Gy
D) 80-84 Gy
E) ≥ 85 Gy
Number of brachytherapy fractions
A) 1 or 2
B) 3
C) 4
D) 5
E) 6
Which dose volume constraints are used for organs at risk?
A) Bladder
B) Rectum
C) Sigmoid
D) Vagina
Table 3.1: Pre-workshop questionnaire.
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3.2 Online delineation workshop structure
The number of participants needed to ﬁnd statistically signiﬁcant diﬀerences (number
needed to treat (NNT)) for inter and intraobserver contouring variability was calculated,
resulting in 50 participants. Thus, two to four participants were invited from each centre
(proportional to the gynaecological team) to participate in an ODW in LACC. The goal
was an estimated participation from the 22 RAIDs clinical centres of approximately 50
clinicians Table 1.2. This exceeded the capacity of the ODW, so two identical workshops
were planned.
Between two and four participants from each centre were enrolled in an ODW in LACC.
A technical partnership was agreed upon with the European Society for Radiotherapy &
Oncology (ESTRO) and the methodology resembled the one used in Fellowship in Anatom-
ical deLineation and CONtouring (FALCON) ESTRO ODW. The live presentations were
performed via WebEx conferencing and the contouring was on the FALCON EduCaseTM
online contouring platform.
Training was provided by an expert in the ﬁeld, CHM, and for every 10 participants
there was one tutor. The tutors were radiation oncologists with experience in the ﬁeld of
cervical cancer, already trained to use the FALCON EduCaseTM online contouring system.
Tutors gave the participating clinicians support to assist them with the use of FALCON
EduCaseTM. They also assisted by answering basic questions about the use of the contouring
guidelines, and compiled more speciﬁc contouring questions to be answered by the expert,
CHM, during the live WebEx sessions. The live sessions were completed in 3 weeks and the
participants delineated both the EBRT treatment on computed tomography (CT) as well as
the subsequent BT treatment for the same clinical case. The BT treatment was contoured
on magnetic resonance imaging (MRI). The case and the image sets for both treatments
were reviewed and chosen from the ESTRO FALCON EduCaseTM contouring library with
the expert, CHM.
The live online workshop sessions for the ﬁrst ODW were held on June 20th, June 26th
and July 10th, 2013, and the sessions for the second ODW were held on January 7th, 13th,
and 27th, 2014. The ﬁrst two live online sessions of each workshop were presented by the
tutors.
Session 1: In the ﬁrst presentation they explained how to use the FALCON EduCaseTM
contouring platform. The participants were also explicitly informed (orally and in
writing within the presentation slides), that their contours would be used for a study
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evaluating the ODW and their conformity was requested. No participant revoked their
conformity. The clinicians had a six day period to perform baseline contouring (C1)
(how they contour in daily practice).
Session 2: Contouring guidelines for both EBRT and BT following the An intErnational
study on MRI guided BRachytherapy in locally Advaced CErvical cancer (EMBRACE)
protocol were presented and C1 was reviewed, followed by a question-and-answer ses-
sion. Afterwards, the recommendations from the Groupe Européen de Curiethérapie 
European Society for Radiotherapy and Oncology (Gyn GEC-ESTRO) working group,
EMBRACE1 protocol, a pelvic nodal atlas and two consensus atlases for contouring of
normal tissue in the pelvis were sent to the clinicians to further aid delineation (Haie-
Meder et al., 2005; Taylor et al., 2005; Gay et al., 2012; Gay et al., 2011). Clinicians
were given two weeks to modify their previous contours for the same two image sets.
This was considered the guideline contouring (C2).
Session 3: In the 3rd week the expert in the ﬁeld, CHM, reviewed C1 and C2 and there
was a question-and-answer session.
During the whole ODW period tutors contacted the clinicians and answered their ques-
tions, and the participants were supplied with links to recordings of each live session as well
as the corresponding presentation slides.
Lastly, clinicians recontoured both EBRT and BT treatments after seeing the reference
contours and having their questions answered. This ﬁnal contouring (C3) was done between
1.5-2 months after the last live presentation (session 3), so as to evaluate the long term
teaching impact.
3.3 Description of the clinical case
The 45 year old patient was diagnosed with a FIGO IIIB squamous cell carcinoma of the
cervix. The gynaecological exam revealed a large exo-endophytic growth (85x50x60 mm)
involving the vagina (all fornices 1 cm, anterior wall 4 cm). The tumour inﬁltrated the
right parametrium proximally and the left one up to the pelvic side wall (Figure 3.1,
Figure 3.2). There was no involvement of bladder mucosa (cystoscopy). Abdominopelvic
CT showed a cervical enhancing mass with vaginal involvement, enlarged external, internal,
1http://www.embracestudy.dk
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lower common iliac, and pre-sacral nodes, without paraaortic nodes. The response to EBRT
and concurrent chemotherapy was good, with resulting tumour dimensions of 55x40x30 mm,
free right parametrium, induration of half of the left parametrium, and involvement of 1cm
of the anterior vaginal wall at the time of BT (Figure 3.3, Figure 3.4).
Compulsory volumes for contouring exercises (at minimum required slices for organs at
risk (OAR) and whole region of interest (ROI) for target volume (TV):
• Case 1 - EBRT:
 OAR: Bladder, rectum, bowel, sigmoid.
 cervix, parametria and vaginal gross disease (GTV-p).
 nodal elective volume (CTV-node).
 radiologically pathological lymph nodes to boost (GTV-node).
 GTV-p, uterus and vagina, at least 20 mm below GTV-p (CTV-p).
• Case 2 - BT:
 OAR: Bladder, rectum, sigmoid.
 gross tumor volume (GTV): Macroscopic tumour (if present) at time of BT.
 high risk CTV (HR-CTV): Macroscopic tumour extension at time of BT + whole
cervix + presumed extra cervical tumour extension.
 intermediate risk CTV (IR-CTV): HR-CTV + macroscopic tumour extension at
diagnosis providing a minimal margin of 10 mm to residual disease at time of BT
in direction of potential spread.
3.4 Contour evaluation methodology
Intraobserver variability of each participant was evaluated before and after the presen-
tation of contouring guidelines (C2 vs. C1), before and after the expert review of contours
(C3 vs. C2) and the ﬁnal contour compared to baseline (C3 vs. C1) on one advanced stage
cervical cervical cancer case, for both EBRT and BT treatments. Quantitative and quali-
tative diﬀerences were assessed. Interobserver variability was determined quantitatively by
analyses based on ROI, years of experience in the ﬁeld, and for BT also between centres
using MRI-based image guided brachytherapy (IGBT) and others.
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Figure 3.1: Initial clinical drawing at diagnosis, based on the clinical gynaecological exam.
Figure 3.2: Baseline MRI ﬁndings at diagnosis.
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Figure 3.3: Clinical drawing at the time of BT, based on the clinical gynaecological exam.
Figure 3.4: MRI images at the time of BT.
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E P
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E
P
P
Overlap between contours
Complete overlap:
   DICE score = 1
Partial overlap:
   0 < DICE score < 1
No overlap:
   DICE score = 0
Figure 3.5: Illustration of DICE score, adapted from Zou et al., (2004). E is the Expert contour P is the Participant contour.
The DICE score is deﬁned as 2 VE∩P
VE+VP
where VE∩P is the volume of the intersected contours, VE is the volume of the expert
contour, and VP is the volume of the participant contour.
Contours were reviewed by the expert and tutors responsible of Radiation Therapy Qual-
ity Assurance (RTQA) for the RAIDs project. Quantitatively, they were classiﬁed based on
DICE index values given by the FALCON EduCaseTM output (Figure 3.5). The DICE
score is deﬁned as 2 VE∩P
VE+VP
where VE∩P is the volume of the intersected contours, VE is the
volume of the expert contour, and VP is the volume of the participant contour. The DICE
score has values between 0 (no overlap between contours) and 1 (perfect overlap between
contours) as illustrated in Figure 3.5.
• References for TV (Dimopoulos et al., 2009; Petersen et al., 2007):
 A: Optimal: > 0.81
 B: Average: 0.65  0.81
 C: Suboptimal: < 0.65
• References for OAR (Breunig et al., 2012):
 A: Optimal: > 0.81
 B: Suboptimal: < = 0.81
In MRI-based BT for cervical cancer, Dimopoulos et al., (2009) determined a range of
0.5-0.7 using the conformity index for TV, which converted to DICE is approximately 0.625-
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0.81 (Dimopoulos et al., 2009; Fotina et al., 2012). For OAR, Breunig et al., (2012) obtained
an average DICE of 0.61 for volumes < 8 cm3 and of 0.91 for volumes > 8 cm3, averaging
at 0.76 (Breunig et al., 2012). To simplify the cutoﬀs, making the study easier to interpret,
0.65 and 0.81 were chosen for TV and 0.81 for OAR. Importantly, all statistical analyses
performed in this study were independent of the thresholds which were only used to aid
interpretation and to display the results.
To perform the objective qualitative intraobserver assessment, the FALCON EduCaseTM
contour error distance tool revealed on axial slices where the participant contour was 3 mm
larger or smaller than the expert contour, based on the scalar assessment in the transverse
plane for high risk CTV (HR-CTV) by Petric et al., (2008), in eight directions (anterior,
posterior, right, left, anterolateral right and left and posterolateral right and left) to identify
the most prevalent areas of uncertainties (Petric et al., 2008).
Qualitative Classiﬁcation:
Correct: Participant contour ≤ 3 mm smaller/larger than the expert contour in a given
direction.
Incorrect: Participant contour > 3 mm smaller/larger than the expert contour in a given
direction without a probable clinical impact.
Very incorrect: Participant contour > 3 mm smaller/larger than the expert contour in a
certain direction which for that particular ROI will have a probable clinical impact
(worse coverage of TV/ higher dose to OAR).
Considering that part of the outcome of e-learning courses depends not only on the
quality of the course itself, but also on how the participant perceives and understands it,
a ﬁnal anonymous satisfaction questionnaire adapted from FALCON ESTRO ODW was
administered to the clinicians (see Section 8.2).
3.5 Statistical analysis
3.5.1 Preprocessing of the data
All the DICE scores have been transformed using the logit function, logit(x) = x
1−x . This
transformation allows the DICE scores to asymptotically follow a Gaussian distribution
(Agresti, 2002; Brock, 2013; Zou et al., 2004) which is a prerequisite of the statistical models
we used. As the slice number ranges vary from one ROI to another, the slice numbers have
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been centred on the middle of the range and scale such that the all the ranges vary from -1
to +1 for each ROI. Therefore, when the slice eﬀect is considered in a statistical model, this
centering allows a comparison between the ROI in the middle of their range.
3.5.2 Quantitative analysis of the interobserver variability
Mixed linear model
A mixed linear model was used to assess interobserver variability and ﬁxed eﬀects on
the DICE score. The model in Equation 3.1 was used to analyse the EBRT treatment
and the model in Equation 3.2 was used for the BT treatment and will be referred as to
modelINTER.PART. They are essentially the same models, except that for EBRT the
eﬀect on the imaging technique was not included as it is not relevant (all institutions use
the same imaging technique).
logit(dijkmno) = µ+ αi + βj + γk + (3.1)
αβij +
αγik +
ρiso + νis
2
o +
zmn +
eijkmno
logit(dijklmno) = µ+ αi + βj + γk + λl + (3.2)
αβij +
αγik +
αλil +
ρiso + νis
2
o +
zmn +
eijklmno
where:
µ is the Intercept of the model
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αi is the ﬁxed eﬀect of ROI type i
βj is the ﬁxed eﬀect of the contouring period j, j ∈ {C1, C2, C3}
γk is the ﬁxed eﬀect of a participant's experience k, k ∈ {AI,AE, JR, SR}
λl is the ﬁxed eﬀect of the imaging technique l, l ∈ {MRI,OTHER}
αβij is the interaction the between ﬁxed eﬀects ROI i and contouring period j
αγik is the interaction the between ﬁxed eﬀects ROI i and the experience k
αλil is the interaction the between ﬁxed eﬀects ROI i and the imaging technique l
so is the linear ﬁxed eﬀect of the slice number for the observation o
s2o is the quadratic ﬁxed eﬀect of the slice number for the observation o
ρi is the interaction between the ROI and the linear ﬁxed eﬀect of the slice number
νi is the interaction between the ROI and the quadratic ﬁxed eﬀect of the slice number
zmn is the random eﬀect of the participant m for the ROI type n, n ∈ {OAR, TV }
o is the observation index
eijklmno is the residual error of the model
We assume that the values zmn of the participant random eﬀect follow a Gaussian distri-
bution with a mean equal to 0 and a variance equal to σ2TV , for n = TV , and equal to σ
2
OAR,
for n = OAR. Therefore, we consider in the model that the interobserver variability is dif-
ferent between the TV and the OAR. The values eijklmno follow a Gaussian distribution with
a mean equal to 0 and a variance equal to σ2R. Fixed eﬀects are noted in Greek characters
(ROI type, contouring period, experience, imaging technique for BT, linear and quadratic
eﬀects of slice number) while the random eﬀect is noted in Latin characters (participant
eﬀect for the ROI type). The purpose of the mixed model is to estimate both ﬁxed and
random eﬀects at the same time. The random part of the model allows the decomposition of
the variance between diﬀerent components: the variance due to the interobserver variability
and the residual variance (which is the unexplained variance by the model).
We used the lme4 (Bates et al., 2015) and lmerTest (Kuznetsova et al., 2016) to estimate
the parameters of both models.
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Pairwise comparisons
As the model considers many diﬀerent eﬀects and the design of the study is unbalanced
(we do not have the same number of observations for the diﬀerent conditions), we used the
least-squares means (in short lsmeans) to obtain the average of an eﬀect of interest adjusted
over all the other eﬀects in the model. For example, if we want to obtain the means of
the DICE scores by ROI for each contouring period, the means will be averaging using the
estimated means over the other eﬀects. For this purpose, we used the lsmeans package
(Lenth, 2016).
For all pairwise comparisons we corrected the p-values for multiple testing using false
discovery rate (FDR) (Benjamin and Hochberg, 1995).
Intra-class correlation
The repeatability is an important concept to assess the accuracy of measurements. It
expresses the proportion of the total variation that is reproducible among repeated measure-
ments of the same criteria between diﬀerent observers (Nakagawa and Schielzeth, 2010). The
repeatability is often called the intra-class correlation (ICC) and this term will be used from
here on. The ICC varies between 0 (no agreement between observers) and 1 (perfect agree-
ment between observers). The modelINTER.PART considers that the ICC is diﬀerent
for TV and OAR and will be noted ICC.TV and ICC.OAR, respectively:
ICC.TV =
σ2TV
σ2TV + σ
2
R
ICC.OAR =
σ2OAR
σ2OAR + σ
2
R
The conﬁdence intervals of ICC.TV and ICC.OAR were estimated using bootstrap with
1000 random permutations.
3.5.3 Quantitative analysis of the intraobserver variability
Linear model to assess the diﬀerence of DICE score by participant
To assess intraobserver variability between the diﬀerent contouring periods, a linear model
was used. From the model in Equation 3.3 referred as to modelINTRA.PART, we
estimated the diﬀerences of the means of the DICE scores (in logit scale) by participant and
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by ROI over all the slices for all the three pairwise comparisons of the contouring period j
with respect to j′, j > j′, j and j′ ∈ {C1, C2, C3} separately.
logit(dijmo)− logit(dij′mo) = µ+ αi + ζm + αζim + eimo (3.3)
where:
µ is the Intercept of the model
αi is the ﬁxed eﬀect of ROI i
ζm is the ﬁxed eﬀect of the participant m
o is the observation index
eimo is the residual error of the model
The values eijmo follow a Gaussian distribution with a mean equal to 0 and a variance
equal to σ2R. We used the least-squares means to estimate the parameters of the model.
Linear model to assess the DICE score by participant
To asses the DICE score by participant, a linear model with the same eﬀects as the Equa-
tion 3.3 was used. From the model in Equation 3.4 referred as tomodelSCORE.PART,
we estimated the means of the DICE scores (in logit scale) by participant and by ROI over
all the slices for every contouring period j, j ∈ {C1, C2, C3} separately.
logit(dijmo) = µ+ αi + ζm + αζim + eimo (3.4)
Fisher's exact test to assess if the number of participants who improved is sig-
niﬁcant
From the model in Equation 3.3, we have a p-value by participant and by ROI. Those
p-values assess the signiﬁcance of the diﬀerences of the means of the DICE scores (in logit
scale) between two consecutive contouring periods. As we used bilateral intervals with 95%
conﬁdence, we consider the diﬀerence being signiﬁcant if the p-value is lower than 5%. As
we have at lot of p-values, we expected to have 2.5% (since the interval is bilateral) of the
participants to improve by chance under the null hypothesis. We test if the proportion of
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participants who improved is signiﬁcantly greater than 2.5%. Note that we used the same
approach for participants performing worse (since we expected to have signiﬁcant p-values for
some participants but being just false negatives). These two tests will be noted FEtestbetter
and FEtestworse.
Fisher's exact test to assess the relationship between the participants who im-
proved with respect to other covariates
From the model in Equation 3.3 and the p-values obtained, we deﬁned by ROI and by
participant two categories:
1. Better
2. Not better (i.e. same or worse)
Using a Fisher's exact test, we assessed whether these two categories where associated
with the other following covariates: inst, exp, img or ROI.type. These tests will be noted
FEtestinst, FEtestexp, FEtestimg and FEtestROI.type respectively.
3.5.4 Qualitative analysis of the intraobserver variability
In Section 3.4, three qualitative classiﬁcations of the contours have been deﬁned (cor-
rect, incorrect and very incorrect). In this section, we deﬁned statistical models to assess
whether the participants improved between the diﬀerent contouring periods by comparing
the proportions of correct contours. The proportions of correct contours were calculated by
ROI (pijv) or by ROI.type (pnjv) for each contouring period and each variable v ∈ {alatl,
alatr, ant, inf, l, platl, platr, post, r, sup}. To assess whether there was a diﬀerence between
the proportions between the diﬀerent contouring periods (for example, are the proportions
pgtv,C1,inf and pgtv,C2,inf diﬀerent?), we used the test of McNemar (McNemar, 1947). It is
a chi-square based statistic used to compare proportions on paired data (since we want to
assess whether the participant improved between the diﬀerent contouring periods).
3.5.5 Statistical software and reproductibility
We used R software (R Core Team, 2016) for statistical data analysis and ggplot2 for
graphics (Wickham, 2009). An automated reproduction of this analysis may be performed
by using the scripts and data included in the supplementary information provided in the
article Rivin del Campo et al., (2017).
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4.1 Descriptive statistics
Seventeen participating Rational molecular Assessments and Innovative Drug Selection
(RAIDs) centres answered the preworkshop questionnaire assessing their everyday prac-
tice (Table 4.1). Contours were submitted by participants from 14 of 22 RAIDs centres
(Table 4.1).
Forty-six participants were enrolled of which nine submitted delineations for all contour-
ing periods for external beam radiotherapy (EBRT) and brachytherapy (BT) (Table 4.2).
A description of the participant population which submitted contours by their level of expe-
rience is presented in Table 4.3.
The histograms of the DICE values (in logit scale) for EBRT and BT treatments are
presented in Figure 4.1.
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Table 4.1: Preworkshop questionnaire reﬂecting daily practice in each centre (Rivin del Campo et al., 2017).
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Table 4.2: Participants enrolled in the online delineation workshops which submitted contours for each contouring period.
Abbreviations: EBRT: External beam radiotherapy; BT: Brachytherapy; OAR: Organs at risk; TV: Target volumes.
Table 4.3: Description of the participant population which submitted contours, by level of experience.
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a) EBRT
b) BT
Figure 4.1: Distribution of DICE scores (in logit scale) for EBRT and BT. The thresholds 0.65 and 0.81 (used to deﬁne the
optimality of contours) are indicated in the logit scale.
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4.2 Noteworthy statistical speciﬁcations and general sum-
mary of results
4.2.1 Analysis of the participants who left the study
We have deﬁned the variable has.left to identify the participants who participated to ﬁnal
contouring (C3) (has.left = NO) and participants who left the study, whether it be after
baseline contouring (C1) or guideline contouring (C2) (has.left = YES ). Using the same linear
mixed model (without the contouring period eﬀect), we assessed the eﬀect of the variable
has.left on the DICE score at C1 contouring attempt, to evaluate whether the baseline
DICE score had an inﬂuence on participants adherence to the online delineation workshop
(ODW). Using Fisher's exact test, we also assessed the association between this variable and
the centre or the experience. Importantly, for both EBRT and BT, the Table 4.4 shows that
the variable has.left has no signiﬁcant eﬀect on the DICE score at C1, and no association
with the centre or experience (all the p-values are > 0.05).
Hypothesis H0 Statistical test EBRT BT
Has the variable has.left an eﬀect on the DICE
score at C1?
Fisher's test of type III with Satterthwaite ap-
proximation for degrees of freedom
0.8294 0.5892
Is there an association between the variable
has.left and the institution?
Fisher's exact test 0.10 0.11
Is there an association between the variable
has.left and the position?
Fisher's exact test 0.70 0.72
Table 4.4: P-values for the diﬀerent hypotheses tested to assessed the eﬀect of the variable has.left for both EBRT and BT.
The answer to the Hypothesis tested is Yes when the p-value is < 0.05.
4.2.2 Cutoﬀ points for the DICE scores
A veriﬁcation of the adequacy of the cutoﬀ points used in this study was performed by
examining the distribution of the pooled data for both EBRT and BT treatments over all
contouring periods. In the case of the organs at risk (OAR), the ﬁrst quartile is 0.8, and for
target volume (TV) the ﬁrst quartile is 0.6 and the third quartile is 0.86. These quartiles
are for the most part consistent with the employed cutoﬀ points (0.65 and 0.81).
4.2.3 Summary of the results
A summary of the main results are presented in Table 4.5.
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Table 4.5: Results for both the interobserver and intraobserver quantitative / qualitative analyses. All of the reported results
were statistically signiﬁcant ( p-values < 0.05) (Rivin del Campo et al., 2017).
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4.3 Quantitative interobserver variability
This section presents the results of modelINTER.PART from Equation 3.1 and
Equation 3.2 for EBRT and BT, respectively.
4.3.1 Evaluation of the diﬀerent eﬀects and their interactions on
the DICE score
All of the interactions analysed were highly signiﬁcant (p-values < 0.001) and all eﬀects
had a repercussion on DICE scores (Table 4.6 and Table 4.7 give the Type III sum of
squares and associated p-values for the all the eﬀects included in the models).
Sum Sq Mean Sq NumDF DenDF F.value Pr(>F)
ROI 3311.58 473.08 7.00 390.71 1057.82 0.0000
c 10.43 5.22 2.00 6100.97 11.66 0.0000
exp 0.87 0.29 3.00 25.68 0.65 0.5910
slice 0.05 0.05 1.00 7464.78 0.12 0.7309
slice2 419.67 419.67 1.00 7464.26 938.39 0.0000
ROI:c 91.67 6.55 14.00 7211.05 14.64 0.0000
ROI:slice 349.89 49.98 7.00 7452.21 111.77 0.0000
ROI:slice2 170.73 24.39 7.00 7459.58 54.54 0.0000
ROI:exp 213.20 10.15 21.00 291.47 22.70 0.0000
Table 4.6: Analysis of Variance Table (on the ﬁxed eﬀects) of type III with Satterthwaite approximation for degrees of
freedom for EBRT (Rivin del Campo et al., 2017). The model is computed on logit scale and corresponds to Equation 3.1.
Abbreviations - Sum Sq: sum of squares of the eﬀect; Mean Sq: mean squares of the eﬀect (Mean Sq = Sum Sq / NumDF);
NumDF: Degrees of freedom of the numerator of the Fisher's test statistics; DenDF: Degrees of freedom of the denominator of
the Fisher's test statistics: F.value: value of the Fisher's test; Pr(>F): p-value of the Fisher's test.
Sum Sq Mean Sq NumDF DenDF F.value Pr(>F)
ROI 222.99 44.60 5.00 211.20 106.26 0.0000
c 11.62 5.81 2.00 3360.51 13.84 0.0000
exp 1.06 0.35 3.00 26.36 0.84 0.4817
img 1.58 1.58 1.00 26.31 3.77 0.0630
slice 45.39 45.39 1.00 3489.11 108.14 0.0000
slice2 436.40 436.40 1.00 3494.02 1039.77 0.0000
ROI:c 11.50 1.15 10.00 3467.90 2.74 0.0023
ROI:img 10.99 2.20 5.00 151.72 5.24 0.0002
ROI:slice 292.26 58.45 5.00 3487.88 139.27 0.0000
ROI:slice2 155.72 31.14 5.00 3487.63 74.20 0.0000
ROI:exp 25.99 1.73 15.00 152.42 4.13 0.0000
Table 4.7: Analysis of Variance Table (on the ﬁxed eﬀects) of type III with Satterthwaite approximation for degrees of freedom
for BT. The model is computed on logit scale and corresponds to Equation 3.2. Abbreviations - Sum Sq: sum of squares of
the eﬀect; Mean Sq: mean squares of the eﬀect (Mean Sq = Sum Sq / NumDF); NumDF: Degrees of freedom of the numerator
of the Fisher's test statistics; DenDF: Degrees of freedom of the denominator of the Fisher's test statistics: F.value: value of
the Fisher's test; Pr(>F): p-value of the Fisher's test.
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The models from Equation 3.1 and Equation 3.2 clearly represent the quadratic rela-
tionship between DICE score and slice number, capturing eﬃciently the parabolic eﬀect of
the slice number on the DICE scores (Figure 4.2) for both EBRT and BT.
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a) EBRT
b) BT
Figure 4.2: Means of the DICE scores (1 being perfect concordance between the participant and the expert; 0 being
no concordance) along the three contouring periods, of all participants, by ROI according to the slice number. The lines
correspond to the mean of the DICE score as predicted by the mixed models (from Equation 3.1 and Equation 3.2 for
EBRT and BT respectively) while the dots are the means estimated from the raw data without any statistical model (Rivin
del Campo et al., 2017). 55
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4.3.2 Pairwise comparisons
The pairwise comparisons and corresponding plots are given in:
• Figure 4.3 and Table 4.8 for ROI and contouring period for EBRT
• Figure 4.4 and Table 4.9 for ROI and contouring period for BT
• Figure 4.5 and Table 4.10 for ROI and experience for EBRT
• Figure 4.6 and Table 4.11 for ROI and experience for BT
• Figure 4.7 and Table 4.12 for ROI and imaging technique for BT
Comparison between contouring period for each ROI
The pairwise comparisons for both EBRT and BT treatments between contouring periods
by ROI are reported in Table 4.5 and detailed in Table 4.8 and Table 4.9. For EBRT
and BT in C2 vs. C1 there was signiﬁcant improvement, for the most part for TV, with no
signiﬁcant decrease. When considering C3 vs. C1 in EBRT and BT there was also a signif-
icant increase for certain TV with only a signiﬁcant decrease for radiologically pathological
lymph nodes to boost (GTV-node). However, in C3 vs. C2 for both treatments there was a
signiﬁcant decrease for two TV in EBRT and two OAR (no decrease for TV in BT), with a
signiﬁcant increase for nodal elective volume (CTV-node).
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comparison estimate p-value
bladder,C1 - bladder,C2 -0.01 0.85
bladder,C1 - bladder,C3 -0.04 0.51
bowel region,C1 - bowel region,C2 -0.13 0.04 *
bowel region,C1 - bowel region,C3 0.10 0.22
CTV node,C1 - CTV node,C2 -0.11 0.00 **
CTV node,C1 - CTV node,C3 -0.44 0.00 ***
CTV-p,C1 - CTV-p,C2 -0.19 0.00 ***
CTV-p,C1 - CTV-p,C3 0.05 0.30
GTV node,C1 - GTV node,C2 -0.19 0.00 ***
GTV node,C1 - GTV node,C3 0.42 0.00 ***
GTV-p,C1 - GTV-p,C2 -0.05 0.36
GTV-p,C1 - GTV-p,C3 -0.15 0.03 *
rectum,C1 - rectum,C2 -0.05 0.39
rectum,C1 - rectum,C3 -0.10 0.24
sigmoid,C1 - sigmoid,C2 -0.04 0.67
sigmoid,C1 - sigmoid,C3 -0.11 0.35
bladder,C2 - bladder,C3 -0.03 0.60
bowel region,C2 - bowel region,C3 0.23 0.01 **
CTV node,C2 - CTV node,C3 -0.32 0.00 ***
CTV-p,C2 - CTV-p,C3 0.25 0.00 ***
GTV node,C2 - GTV node,C3 0.61 0.00 ***
GTV-p,C2 - GTV-p,C3 -0.10 0.16
rectum,C2 - rectum,C3 -0.05 0.58
sigmoid,C2 - sigmoid,C3 -0.07 0.54
Table 4.8: Pairwise comparisons between contouring period for each ROI for EBRT from model Equation 3.1. The estimates
correspond to the diﬀerence between the two conditions in the logit scale. The p-values have been corrected for multiple testing
using FDR. Signiﬁcant p-values are indicated by *.
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Figure 4.3: Lsmeans estimates by ROI and contouring period for EBRT. P-values for all pairwise comparisons are listed in
Table 4.8.
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comparison estimate p-value
bladder,C1 - bladder,C2 -0.15 0.01 *
bladder,C1 - bladder,C3 0.12 0.12
GTV,C1 - GTV,C2 -0.30 0.00 ***
GTV,C1 - GTV,C3 -0.09 0.42
HR-CTV,C1 - HR-CTV,C2 -0.24 0.00 ***
HR-CTV,C1 - HR-CTV,C3 -0.16 0.02 *
IR-CTV,C1 - IR-CTV,C2 -0.19 0.00 ***
IR-CTV,C1 - IR-CTV,C3 -0.16 0.01 *
rectum,C1 - rectum,C2 0.04 0.51
rectum,C1 - rectum,C3 0.07 0.40
sigmoid,C1 - sigmoid,C2 -0.07 0.47
sigmoid,C1 - sigmoid,C3 -0.03 0.81
bladder,C2 - bladder,C3 0.27 0.00 ***
GTV,C2 - GTV,C3 0.21 0.07
HR-CTV,C2 - HR-CTV,C3 0.08 0.31
IR-CTV,C2 - IR-CTV,C3 0.03 0.65
rectum,C2 - rectum,C3 0.03 0.72
sigmoid,C2 - sigmoid,C3 0.04 0.74
Table 4.9: Pairwise comparisons between contouring period for each ROI for BT from model Equation 3.2. The estimates
correspond to the diﬀerence between the two conditions in the logit scale. The p-values have been corrected for multiple testing
using FDR. Signiﬁcant p-values are indicated by *.
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Figure 4.4: Lsmeans estimates by ROI and contouring period for BT. P-values for all pairwise comparisons are listed in
Table 4.9.
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Comparison between experience for each ROI
The analysis of the EBRT treatment (Table 4.10) regarding the experience eﬀect showed
that experienced specialists performed signiﬁcantly better than junior residents for sigmoid
and signiﬁcantly worse than less experienced specialists and senior residents for GTV-node
and than junior residents for cervix, parametria and vaginal gross disease (GTV-p). Less
experienced specialists had performed signiﬁcantly better than junior residents for GTV-
node and sigmoid, and than senior residents for sigmoid. In the case of senior and junior
residents, there were only signiﬁcant diﬀerences between them for GTV-node and GTV-p.
For BT the only signiﬁcant diﬀerence was that experienced specialists had better results
than senior residents for sigmoid (Table 4.5 and Table 4.11).
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comparison estimate p-value
bladder,AE - bladder,AI 0.11 0.23
bladder,AE - bladder,JR 0.01 0.93
bladder,AE - bladder,SR 0.12 0.21
bowel region,AE - bowel region,AI -0.00 1.00
bowel region,AE - bowel region,JR -0.22 0.08
bowel region,AE - bowel region,SR -0.03 0.83
CTV node,AE - CTV node,AI -0.06 0.77
CTV node,AE - CTV node,JR 0.16 0.52
CTV node,AE - CTV node,SR 0.12 0.57
CTV-p,AE - CTV-p,AI 0.07 0.75
CTV-p,AE - CTV-p,JR -0.08 0.78
CTV-p,AE - CTV-p,SR -0.33 0.11
GTV node,AE - GTV node,AI -0.61 0.00 **
GTV node,AE - GTV node,JR 0.41 0.11
GTV node,AE - GTV node,SR -0.96 0.00 ***
GTV-p,AE - GTV-p,AI -0.31 0.13
GTV-p,AE - GTV-p,JR -0.74 0.00 **
GTV-p,AE - GTV-p,SR -0.14 0.53
rectum,AE - rectum,AI 0.02 0.90
rectum,AE - rectum,JR 0.07 0.58
rectum,AE - rectum,SR 0.01 0.94
sigmoid,AE - sigmoid,AI -0.10 0.49
sigmoid,AE - sigmoid,JR 0.39 0.01 *
sigmoid,AE - sigmoid,SR 0.19 0.14
bladder,AI - bladder,JR -0.10 0.40
bladder,AI - bladder,SR 0.01 0.96
bowel region,AI - bowel region,JR -0.22 0.16
bowel region,AI - bowel region,SR -0.03 0.88
CTV node,AI - CTV node,JR 0.23 0.40
CTV node,AI - CTV node,SR 0.18 0.42
CTV-p,AI - CTV-p,JR -0.15 0.60
CTV-p,AI - CTV-p,SR -0.40 0.08
GTV node,AI - GTV node,JR 1.02 0.00 ***
GTV node,AI - GTV node,SR -0.35 0.14
GTV-p,AI - GTV-p,JR -0.42 0.12
GTV-p,AI - GTV-p,SR 0.18 0.45
rectum,AI - rectum,JR 0.06 0.68
rectum,AI - rectum,SR -0.01 0.96
sigmoid,AI - sigmoid,JR 0.49 0.00 **
sigmoid,AI - sigmoid,SR 0.29 0.04 *
bladder,JR - bladder,SR 0.11 0.38
bowel region,JR - bowel region,SR 0.19 0.16
CTV node,JR - CTV node,SR -0.04 0.88
CTV-p,JR - CTV-p,SR -0.25 0.35
GTV node,JR - GTV node,SR -1.36 0.00 ***
GTV-p,JR - GTV-p,SR 0.60 0.03 *
rectum,JR - rectum,SR -0.06 0.65
sigmoid,JR - sigmoid,SR -0.20 0.23
Table 4.10: Pairwise comparisons between experience for each ROI for EBRT from model Equation 3.1. The estimates
correspond to the diﬀerence between the two conditions in the logit scale. The p-values have been corrected for multiple testing
using FDR. Signiﬁcant p-values are indicated by *.
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Figure 4.5: Lsmeans estimates by ROI and experience for EBRT. P-values for all pairwise comparisons are listed inTable 4.10.
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comparison estimate p-value
bladder,AE - bladder,AI 0.05 0.76
bladder,AE - bladder,JR 0.02 0.90
bladder,AE - bladder,SR -0.01 0.95
GTV,AE - GTV,AI 0.20 0.67
GTV,AE - GTV,JR -0.13 0.83
GTV,AE - GTV,SR 0.19 0.69
HR-CTV,AE - HR-CTV,AI 0.70 0.10
HR-CTV,AE - HR-CTV,JR 0.58 0.26
HR-CTV,AE - HR-CTV,SR 0.13 0.79
IR-CTV,AE - IR-CTV,AI 0.64 0.13
IR-CTV,AE - IR-CTV,JR 0.52 0.31
IR-CTV,AE - IR-CTV,SR 0.09 0.85
rectum,AE - rectum,AI 0.24 0.06
rectum,AE - rectum,JR 0.16 0.31
rectum,AE - rectum,SR 0.20 0.16
sigmoid,AE - sigmoid,AI 0.20 0.21
sigmoid,AE - sigmoid,JR 0.20 0.32
sigmoid,AE - sigmoid,SR 0.39 0.02 *
bladder,AI - bladder,JR -0.02 0.91
bladder,AI - bladder,SR -0.05 0.73
GTV,AI - GTV,JR -0.32 0.57
GTV,AI - GTV,SR -0.01 0.99
HR-CTV,AI - HR-CTV,JR -0.12 0.84
HR-CTV,AI - HR-CTV,SR -0.57 0.21
IR-CTV,AI - IR-CTV,JR -0.12 0.84
IR-CTV,AI - IR-CTV,SR -0.55 0.23
rectum,AI - rectum,JR -0.08 0.67
rectum,AI - rectum,SR -0.04 0.79
sigmoid,AI - sigmoid,JR 0.00 0.99
sigmoid,AI - sigmoid,SR 0.19 0.29
bladder,JR - bladder,SR -0.03 0.87
GTV,JR - GTV,SR 0.32 0.59
HR-CTV,JR - HR-CTV,SR -0.45 0.42
IR-CTV,JR - IR-CTV,SR -0.43 0.45
rectum,JR - rectum,SR 0.04 0.85
sigmoid,JR - sigmoid,SR 0.19 0.40
Table 4.11: Pairwise comparisons between experience for each ROI for BT from model Equation 3.2. The estimates
correspond to the diﬀerence between the two conditions in the logit scale. The p-values have been corrected for multiple testing
using FDR. Signiﬁcant p-values are indicated by *.
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Figure 4.6: Lsmeans estimates by ROI and experience for BT. P-values for all pairwise comparisons are listed in Table 4.11.
63
Radiotherapy quality control in cervical cancer
Eﬀect of the MRI-imaging technique for the BT treatment
Regarding the imaging technique, the INTER.PART model from Equation 3.2 was
used to analyse interobserver variability between centres that used magnetic resonance imag-
ing (MRI) based image guided brachytherapy (IGBT) and those which did not. Centres using
MRI based IGBT did signiﬁcantly better than those which used other techniques (computed
tomography (CT), X-Ray, ultrasound (US)) for high risk CTV (HR-CTV) (Table 4.12,
Figure 4.7).
comparison estimate p-value
bladder,MRI - bladder,OTHER 0.00 0.97
GTV,MRI - GTV,OTHER 0.41 0.21
HR-CTV,MRI - HR-CTV,OTHER 0.78 0.02 *
IR-CTV,MRI - IR-CTV,OTHER 0.53 0.10
rectum,MRI - rectum,OTHER 0.16 0.12
sigmoid,MRI - sigmoid,OTHER 0.18 0.15
Table 4.12: Pairwise comparisons between imaging technique for each ROI for BT from model Equation 3.2. The estimates
correspond to the diﬀerence between the two conditions in the logit scale. The p-values have been corrected for multiple testing
using FDR. Signiﬁcant p-values are indicated by *.
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Figure 4.7: Lsmeans estimates by ROI and imaging technique. Signiﬁcant diﬀerence is indicated by *. P-values for all
pairwise comparisons are listed in Table 4.12.
Intra-class correlation
The intra-class correlation (ICC) for interobserver variability was excellent for OAR in
BT (0.92; 95% conﬁdence interval: 0.86-0.96), OAR in EBRT (0.96; 95% conﬁdence interval:
0.93-0.98) and TV in EBRT (0.78 - 95% conﬁdence interval: 0.68-0.88) while it was fair for
64
Chapter 4 Results 4.4 Quantitative intraobserver variability
TV in BT (0.51; 95% conﬁdence interval: 0.39-0.68). The low ICC for TV in BT highlights
the diﬃculty of participants to agree on contours, whether they usually contour on MRI or
not (the imaging technique was taken into account in modelINTER.PART).
4.4 Quantitative intraobserver variability
This section presents the results of Equation 3.3 referred as to modelINTRA.PART
and Equation 3.4 referred as to modelSCORE.PART.
4.4.1 Diﬀerence of the DICE scores between C2 vs. C1
Figure 4.8 and Figure 4.9 show the diﬀerence of DICE scores by participant between
C2 vs. C1 by region of interest (ROI) for EBRT and BT, respectively (only the plots for
the comparison between C2 vs. C1 are reported in the present manuscript to facilitate the
lecture of this thesis, all the other plots for C3 vs. C2 and C3 vs. C1 are available in the
supplementary materials in Rivin del Campo et al., 2017). The values plotted correspond
to the estimates obtained by modelINTRA.PART from Equation 3.3. The participants
improve when the lsmean value is positive and the conﬁdence interval does not overlap 0.
The Table 4.13 provides the diﬀerent Fisher's exact tests to assess the signiﬁcance of the
improvement and its association with other eﬀects.
The Figure 4.10 represents the scatterplot of the DICE score between C2 vs. C1.
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Figure 4.8: Diﬀerence of the DICE scores by participant between C2 vs. C1 by ROI. The values are the lsmeans estimates
with 95% conﬁdence interval (logit scale) obtained from modelINTRA.PART for EBRT. Participants improve when the
lsmean value is positive and the conﬁdence interval does not overlap 0.
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Figure 4.9: Diﬀerence of the DICE scores by participant between C2 vs. C1 by ROI. The values are the lsmeans estimates
with 95% conﬁdence interval (logit scale) obtained from modelINTRA.PART for BT. Participants improve when the lsmean
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Hypothesis tested for C2 vs. C1 p-value for EBRT p-value for BT
Does participant signiﬁcantly improve (FEtestbetter)? 0.00 *** 0.00 ***
Does participant signiﬁcantly decrease (FEtestworse)? 0.75 0.72
Does the improvement depends on ROI.type (FEtestROI.type)? 0.03 * 0.00 ***
Does the improvement depends on inst (FEtestinst)? 0.00 *** 0.89
Does the improvement depends on exp (FEtestexp)? 0.26 0.48
Does the improvement depends on img (FEtestimg)? 1.00
Hypothesis tested for C3 vs. C1 p-value for EBRT p-value for BT
Does participant signiﬁcantly improve (FEtestbetter)? 0.00 *** 0.09
Does participant signiﬁcantly decrease (FEtestworse)? 0.16 0.44
Does the improvement depends on ROI.type (FEtestROI.type)? 0.57 0.01 *
Does the improvement depends on inst (FEtestinst)? 0.44 0.05
Does the improvement depends on exp (FEtestexp)? 0.62 0.02 *
Does the improvement depends on img (FEtestimg)? 0.40
Hypothesis tested for C3 vs. C2 p-value for EBRT p-value for BT
Does participant signiﬁcantly improve (FEtestbetter)? 0.01 ** 1.00
Does participant signiﬁcantly decrease (FEtestworse)? 0.05 0.09
Does the improvement depends on ROI.type (FEtestROI.type)? 0.49 1.00
Does the improvement depends on inst (FEtestinst)? 0.39 1.00
Does the improvement depends on exp (FEtestexp)? 0.46 1.00
Does the improvement depends on img (FEtestimg)? 1.00
Table 4.13: Fisher's exact tests to assess the signiﬁcance of the improvement of the DICE score between the diﬀerent contouring
periods and its association with other eﬀects for EBRT and BT. The answer to the Hypothesis tested is Yes when the p-value
is < 0.05.
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4.5 Qualitative intraobserver variability
In the EBRT treatment, on one hand the percentage of correct contours was signiﬁ-
cantly better between C2 vs. C1 for posterolateral right in TV. When considering each ROI
independently, it was signiﬁcantly better between C2 vs. C1 for CTV-node and GTV-p,
uterus and vagina, at least 20 mm below GTV-p (CTV-p) in the posterior direction, and for
CTV-node in the posterolateral left direction. On the other hand, it was signiﬁcantly worse
between C3 vs. C1 and C3 vs. C2 for anterolateral right and inferior in TV, and signiﬁ-
cantly worse between C3 vs. C2 for posterior and posterolateral left in TV. For independent
ROI, it was signiﬁcantly worse for C3 vs. C2 for anterolateral right for CTV-p and GTV-p,
in the posterolateral left direction for CTV-node and for the inferior direction for CTV-p
(Figure 4.11).
For BT, the percentage of correct contours is signiﬁcantly better between C2 vs. C1 for
right and posterolateral right in TV and between C3 vs. C1 for posterolateral right in OAR,
while it signiﬁcantly worse between C3 vs. C1 and C3 vs. C2 for posterolateral right in
TV. In the case of the individual ROI, it was signiﬁcantly worse between C3 vs. C1 in the
posterolateral right direction for HR-CTV and between C3 vs. C2 in the same direction for
HR-CTV and intermediate risk CTV (IR-CTV) (Figure 4.12).
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Figure 4.11: Diﬀerence of the proportion of correct contours between the diﬀerent contouring periods. The test of McNemar
was used to compare the proportions. Signiﬁcant diﬀerence are indicated by *.
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Figure 4.12: Diﬀerence of the proportion of correct contours between the diﬀerent contouring periods. The test of McNemar
was used to compare the proportions. Signiﬁcant diﬀerences are indicated by *.
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4.6 Satisfaction questionnaire
The scale used for the Organization and Content items went between 1 and 5, with 1
being poor and 5 excellent. The scores for these 20 items for the 20 ODW participants
who responded the satisfaction questionnaire of the 32 that submitted contours ranged from
3.95-4.60 with an average of 4.358 (Table 4.14).
Participants were also asked whether they would follow another ODW, 80% of the par-
ticipating clinicians answered positively, and 85% of them would recommend one.
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First and foremost, it is essential to underscore the innovative use of this online delin-
eation workshop (ODW) to evaluate delineation skills as a dummy run within a multicentre
trial. This is the ﬁrst time this kind of ODW has been used for this purpose within this
context (Grau Eriksen et al., 2014). Recently, other clinical trials have also employed an
ODW following this format as part of their quality assurance programmes. An example
is HYPO-G-01, which has promising initial results submitted as an abstract to the next
European Society for Radiotherapy & Oncology (ESTRO) meeting (ESTRO 37, (HYPOG-
01, https://www.gustaveroussy.fr/en/node/3646 2017)). Other authors have recommended
including training programmes in Radiation Therapy Quality Assurance (RTQA) protocols
(Fokas et al., 2015). The results presented support the feasibility of the ODW as a contour-
ing dummy run within a multicentre trial and its capacity to identify centres with baseline
and subsequent average to optimal contours which are prepared to include patients, while
providing an educational tool for others. The additional contribution of this study is that it
also presents the participants' point of view, which in regard of the results of the post-ODW
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satisfaction questionnaire is quite favourable.
A comprehensive follow-up model was developed within a publication led by the European
Organisation for Research and Treatment of Cancer (EORTC) quality assurance strategic
committee and team, to use individual patient data to establish a possible impact of RTQA
levels on patient outcome (Weber et al., 2014). They found a clear correlation between
survival (both quality-of-life-adjusted and recurrence-free) which augmented along with the
RTQA levels. Notably, with a level 4 RTQA programme there was a gain of 1.8 months
of QALY, compared with a level 2 RTQA. This is much higher than the QALY which is
usually gained in prospective randomised radiotherapy trials. This leads to a very interesting
statement: considering the costs of a tumour recurrence, higher RTQA levels, though costly,
actually induced signiﬁcant savings (Weber et al., 2014).
Speciﬁcally, within the context of cervical cancer, the RTQA programme performed
within the Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally
Advanced Cervical Cancer (INTERLACE) trial resulted in the development of a contouring
atlas (Eminowicz et al., 2016a). As previously mentioned, when this atlas was used within
INTERLACE, the average proportion of protocol compliant delineations for primary clini-
cal target volume (CTV), nodal elective volume (CTV-node), bladder and rectum increased
from 1.8 to 2.7 (diﬀerence of 0.9; 95% conﬁdence interval, 0.3-1.5; p-value = 0.003). Its
use also lowered interobserver contouring variation within INTERLACE (Eminowicz et al.,
2016a).
An issue of utmost importance in delineation studies is the choice of the metrics used
for the comparison. In our experience, it was the the DICE score, however, many diﬀerent
metrics exist, as reported by Taha and Hanbury, (2015). DICE is the metric used most often
to evaluate three-dimensional (3D) medical imaging segmentations, especially to determine
reproducibility. It is an overlap metric, as well as the Jaccard index, the true and false
positive rates (not commonly used, due to their sensibility to the size of the segment) and
the global consistency error. Of note, the correspondence between DICE and distance based
metrics is reduced when the overlap is smaller, which is logical as DICE only takes into
consideration the voxels which are in the region that overlaps, as opposed to distance based
metrics (Taha and Hanbury, 2015). For this reason, DICE is less dependable for small
volumes, explaining low median DICE scores in studies evaluating small volumes, such as
Chung et al., (2015). Thus, adding a distance based metric to our analysis may have resulted
in more robust results. With this intention, the contour error distance tool was developed
within Fellowship in Anatomical deLineation and CONtouring (FALCON) EduCaseTM by
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petition in the context of this thesis. However, it was more within views of an objective
qualitative interpretation of the contouring variability, as it did not supply exact quantitative
results.
5.1 Interobserver validation of the ODW in LACC
It has been both numerically and graphically described in the literature, even speciﬁ-
cally for cervical cancer, that the largest contouring uncertainties are on the cranial and
caudal slices of a volume (Petri£ et al., 2013; Hyeon Joo et al., 2017). This fully agrees with
our results for the quantitative interobserver analysis (Figure 4.2). The most particular
pattern belongs to the bowel, since the expert contour followed individual bowel loops and
instead most participants contoured a bowel bag, although both contouring techniques are
valid (Banerjee et al., 2013). Barillot et al., (2014) highlight how clear contouring deﬁni-
tions should be established for bowel in patients receiving intensity modulated radiotherapy
(IMRT) to the pelvis, especially in cases of pelvic nodal irradiation.
The main reason why the evaluation of interobserver variability was the ﬁrst primary end-
point was it allowed assessment of the overall improvement/detriment of all participants in
the ODW between them, instead of considering only individual variability versus the expert
contour. This is of uttermost importance since the expert contour aﬀects the comparison of
region of interest (ROI), and most often has certain ﬂaws (Vinod et al., 2016; Vinod et al.,
2017). Not surprisingly, the interobserver comparisons for both external beam radiotherapy
(EBRT) and brachytherapy (BT) showed overall more improvement between guideline con-
touring (C2) and baseline contouring (C1) than between ﬁnal contouring (C3) and C1, and
mostly the worse results were between C3 and C2. This seems to indicate that participants
acquired contouring skills after the guideline presentation, and just partially retained this
knowledge 1.5-2 months later. However, a positive point is that the intraobserver analysis
showed that only improvements were signiﬁcant between diﬀerent contouring periods.
As for the results for interobserver variability considering experience in EBRT, experi-
enced specialists had signiﬁcantly worse results than less experienced specialists and senior
residents for radiologically pathological lymph nodes to boost (GTV-node). But this ﬁnding
should be interpreted with caution. A borderline signiﬁcant paraaortic lymph node (though
no positive paraaortic lymph nodes was speciﬁed in the clinical case) and a suspicious left in-
guinal node were visible on the EBRT computed tomography (CT) image set. The latter was
considered inﬂammatory by CHM in the live sessions. Thus, interestingly, this may highlight
77
Radiotherapy quality control in cervical cancer
that less experienced specialists and senior residents fully integrated all the clinical infor-
mation provided when contouring. As could be expected, less experienced specialists, with
more experience, did better than junior residents for GTV-node and than junior and senior
residents for sigmoid, as senior residents did better than junior residents for GTV-node (all
results were signiﬁcant). Unexpectedly, junior residents had signiﬁcantly better results than
senior residents for cervix, parametria and vaginal gross disease (GTV-p). There was only
one signiﬁcant diﬀerence related to experience for BT: experienced specialists contoured bet-
ter the sigmoid than senior residents. Interestingly, results from the An intErnational study
on MRI guided BRachytherapy in locally Advaced CErvical cancer (EMBRACE) dummy run
may somewhat explain this, as they found that the organ at risk with the most divergence
was the sigmoid, in 7 of the 28 centres (Kirisits et al., 2015).
A qualitative analysis of the interobserver variability was also contemplated within the
ﬁrst primary objective. When addressing this analysis from a statistical point of view, it was
not feasible due to several reasons. First, the data from the qualitative analysis are by nature
discrete. The statistical model modelINTER.PART we proposed for the interobserver
variability in the quantitative analysis cannot be applied on discrete data. Second, the
qualitative classiﬁcation of contours with the three modalities correct, incorrect, very
incorrect has been performed for eight diﬀerent directions of space. Therefore, as opposed
to the DICE score, there is not a unique qualitative score that could be used to evaluate
the interobserver variability. Third, even if this score would exist, it should be inferred
automatically from the contours that have been submitted, while the qualitative classiﬁcation
has been performed from a visual inspection, done manually. Considering this last task would
be very long and tedious, it would be very diﬃcult to gather the necessary data. Of note,
Petric et al., (2008) did manage to perform a qualitative analysis of interobserver variability
for a BT treatment. They measured manually the distances between the centre of the uterine
tandem to the high risk CTV (HR-CTV) contour of both observers in the study, in the eight
directions of space. The diﬀerence was that they only did this for one ROI, as opposed to
the 14 ROI analysed in this study, and for only two observers instead of up to 30 for C1 for
the BT treatment in our experience.
Another possible way to analyse qualitative interobserver variability may have been by
inclusion of anatomic regions, as performed by Fairchild et al., (2014) and Hyeon Joo et al.,
(2017). Unfortunately, in the context of the ODW, the workshop structure would need to
be modiﬁed for this. When it was performed, all necessary regions included were speciﬁed,
except for the lymph node stations. Similarly to the (Hyeon Joo et al., 2017), a frequent
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diﬃculty shown by the participants when contouring the CTV-node was including the 7 mm
margin around the pelvic vessels, although speciﬁc recommendations were provided (Hyeon
Joo et al., 2017; Taylor et al., 2007).
5.2 Intraobserver validation of the ODW in LACC
The most interesting aspect of the quantitative results for intraobserver variability is
that only the improvements of the participant contours for each clinician were signiﬁcant
between contouring periods (Table 4.13). For C2 vs. C1 the improvement depended on
ROI type for the contours for both treatments and also on institution for the EBRT treatment
contours. Conversely from the EBRT treatment, for BT overall treatment contours there
was no signiﬁcant improvement between C3 vs. C1 and C3 vs. C2. On the contrary of what
could be assumed, the use of magnetic resonance imaging (MRI) imaging for planning of BT
treatments had no signiﬁcant impact from the intraobserver point of view.
In the literature, a qualitative interobserver analysis did not show diﬀerences in the 8
directions of space for HR-CTV contours (Petric et al., 2008). The experience performed
for this thesis evidenced qualitative intraobserver diﬀerences for correct contours which were
signiﬁcant for certain directions (better or worse) for EBRT. However, there was no obvious
explanation to this phenomenon, and these diﬀerences did not seem to have a clear poten-
tial clinical impact. Otherwise, for BT, the signiﬁcant improvement towards the right and
posterolateral right for target volume (TV) in C2 vs. C1 most probably was because the left
parametrial invasion made participants focus more on the left portion of the TV than on
the right during C1, and they improved after the guideline session. But unfortunately this
improvement was shortlived, and in C3 they went back to their old ways, doing signiﬁcantly
worse for posterolateral right TV in C3 vs. C1 and C2.
Centres were identiﬁed with participants with suboptimal baseline contours which did not
signiﬁcantly improve and change categories (to average or optimal) in subsequent contouring
periods. Clinicians from these centres were invited to follow-up speciﬁc, onsite training, in
standard radiochemotherapy for locally advanced cervical cancer (LACC), at our centre.
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5.3 Evaluation of the teaching methodology of the ODW
in LACC
The results of the submitted student satisfaction questionnaires were excellent. The best
satisfaction results were reﬂected for reaching the goals stated for the ODW, the expert
presentation, the support oﬀered by ESTRO and the tutors, the language used, and in
agreement that the information presented was well balanced and supported by the evidence.
When asked whether they considered the learning experience as equivalent to face-to-face
the average response was 4.05 on a scale of 1-5, which shows a good acceptance of the virtual
nature of the ODW. The average response for the overall rating of the ODW was even better,
4.4. Thus, the clinicians clearly supported not only this innovative workshop format, but
they also valued well its organisation, support and content.
The average answer of participants was 3.95 on a scale of 1-5 for evaluation of the FAL-
CON EduCaseTM contouring platform, reﬂecting a good understanding of its use. A previous
publication has recommended each centre use their own treatment planning system (TPS)
for contouring of dummy runs to ease the use of the knowledge acquired in routine clinical
practice (Clark et al., 2009). Though this approach may be useful, especially for the imple-
mentation of new modern radiotherapy techniques in an institution within a multicentre trial,
from a practical standpoint it requires more resources to transfer image sets and contours.
Conversely, FALCON EduCaseTM is a fully virtual online contouring platform, which does
not require downloading of any modules to be functional, and is accessible from anywhere,
anytime. Its accessibility may also favour compliance with the dummy run exercises.
Another strong point of the ODW blended learning experience is it allowed immediate
interaction between participants and tutors, and timely interaction with the teaching faculty.
As the ODW was performed before opening Rational molecular Assessments and Innovative
Drug Selection (RAIDs) centres, certain ambiguities in the RAIDs contouring protocol were
detected by participant-tutor interaction. This resulted in the corresponding modiﬁcations
of the RAIDs contouring protocol. Similarly, Lo et al., (2014) have found that a large
part of the recommendations to adapt delineations in their contouring study for stereotactic
body radiation therapy (SBRT) in lung cancer were due to either to nonadherence to the
contouring guidelines, or to ambiguities in their interpretation. As in our experience, a
dummy run in the EORTC 22043-30041 trial in postoperative prostate radiotherapy +/-
androgen deprivation therapy achieved improvements in the trial contouring protocol by
pointing out its weak points before patient accrual (Fenton et al., 2013). This indicates the
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need for a clear hands on explanation of delineation guidelines and a continuous review of
the contours to motivate discussions which may bring forth frequent areas of divergence (Lo
et al., 2014).
From the point of view of the e-learning educational experience, an important aspect of
the ODW is that it allows a self-directed path. Each participant may choose to attend live
online sessions, within a blended learning model (with support and interaction with tutors)
and/or follow the session recordings. This ﬂexibility is essential in this context, as the ODW
may be adapted to the physicians' heavy workload (Booth et al., 2009). But unfortunately
this was not eﬀective in all cases, 14 of the initial 46 enrolled participants did not submit
contours. Although, it is to be noted, that the 20 participants who did submit contours and
answered the satisfaction questionnaire considered that the workload demands of the ODW
were realistic (average score of 4.2 on a scale of 1-5).
As previously mentioned, this ODW followed the structure of ESTRO FALCON ODW.
ESTRO has been providing onsite delineation workshops since 2009, and ODW since 2012.
Not only has ESTRO taken action to provide the necessary onsite and online training courses
in contouring for the radiotherapy community, but so has the Royal College of Radiologists
(RCR) (Eminowicz et al., 2016b).
5.4 Analysis of clinician contouring on MRI for BT plan-
ning
Evidence has shown that in MRI image guided brachytherapy (IGBT), MRI especially
allows better visualisation of the vagina and uterus than of the rectum or bladder (Dimopou-
los et al., 2006). This may very well be an explanation for the interobserver quantitative
improvement in HR-CTV and intermediate risk CTV (IR-CTV) for C2 and C3 vs. C1, as
opposed to a detriment for the bladder (C3 vs. C2) (Table 4.5).
It is also interesting to note the signiﬁcant interobserver quantitative improvement for
contouring of HR-CTV for centres doing MRI-IGBT vs. those that do not, showing the
impact of speciﬁc institutional training in MRI-based contouring (Figure 4.7). An inter-
observer contouring comparison has been performed between two centres with a tradition in
MRI-based contouring. In that publication, only mean volumes of IR-CTV diﬀered signiﬁ-
cantly between institutions, but with no signiﬁcant diﬀerences when considering conformity
indices , as could be expected from the world renowned participating institutions (Dimopou-
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los et al., 2009). Thus, they showed that the use of Groupe Européen de Curiethérapie 
European Society for Radiotherapy and Oncology (Gyn GEC-ESTRO) guidelines for IGBT
contouring yields acceptable interobserver variability. In eﬀect, training in contouring and
the use of speciﬁc contouring guidelines may reduce systematic contouring errors (Dimopou-
los et al., 2009).
5.5 Preworkshop questionnaire
Much practical information of the radiotherapy techniques practised within the partic-
ipating RAIDs centres was gathered from the pre-workshop questionnaire. In light of the
publication by Mazeron et al., (2017), special attention may be given to the item: BT
prescription.
Mazeron et al., (2017) have evaluated the relevance of reporting the dose to point A
as in classical BT treatments in the IGBT era. They only found a signiﬁcant relationship
between the dose to point A with total reference air kerma (TRAK) and one IGBT treatment
volume: as a surrogate of the D90 (the dose to 90% of the volume) HR-CTV. The TRAK
is a function of the volume irradiated. The dose to point A increases with the TRAK, as
well as with the decrease of D90 HR-CTV, by a formula involving the HR-CTV volume for
the latter. They did not ﬁnd a direct signiﬁcant correlation between point A doses and D90
HR-CTV, nor with local control, leading them to clearly question the utility of reporting
point A doses for IGBT treatments. But the International Commission for Radiation Units
and measurements. (ICRU) still advocates routine point A reporting in IGBT (Mazeron
et al., 2017) .
In our study, 15 out of 17 participating RAIDs centres performed IGBT. Of them, only
three centres still prescribed to point A, as well as to the HR-CTV. Only one of these
three centres did MRI-based IGBT. However, our questionnaire did not reﬂect whether the
remaining 12 centres doing IGBT included the dose to point A in their treatment reports.
Of note, in the EMBRACE II study, a supplementary planning aim to the IR-CTV and
HR-CTV aims was point A > 65 Gy. Its objective was to guarantee a minimum dose in small
tumours, where contouring uncertainty may cause insuﬃcient tumour treatment coverage.
The Mazeron et al., (2017) patient series showed no diﬀerence in 3-year local control for
small lesions (HR-CTV < 3 cm) between those that received a dose to point A ≥65 Gy or <
65 Gy. Adding this planning aim to these patients would have incurred in a higher dose to
the organs at risk (OAR) with no clear clinical beneﬁt, for the time being (Mazeron et al.,
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2017).
5.6 Limitations of this study
The ﬁrst limitations encountered during this study were organisational. It proved diﬃcult
to locate radiotherapy professionals since the ODW was held before the RAIDs trial opened
in clinical centres. Furthermore, the ﬁrst ODW took place in June-July. In this context,
many clinicians could not participate or only could attend some sessions. Fewer contour sets
were submitted during July (C2), and even less in August-September (C3). Also, aversion of
participating centres to complete radiotherapy credentialing programmes has been previously
reported, and mostly attributed to the time needed to perform these activities (Weber et al.,
2012). This led to only 13 contours being submitted for C3, limiting statistical signiﬁcance
and with a less representative population.
Within the submitted contour sets, not all OAR were contoured for all three contouring
attempts. This is in line with the individual case review (ICR) performed within a previous
study, the EORTC 2203326033/CE5 phase III randomised low grade glioma trial (Fairchild
et al., 2012c). In an average of 1/4 of the cases (range 5-72%) required OAR contours were
absent, and almost 1/3 of the present OAR contours were not correctly contoured (Fairchild
et al., 2012c).
Another limitation, as somewhat previously mentioned, was the use of the DICE index.
It was the only contouring conformity index available as FALCON EduCaseTM output at
the time. This index is less reliable in small ROI volumes. Examples in our study would
be GTV-node, gross tumor volume (GTV) or sigmoid, showing lower concordance because
slight diﬀerences in delineation have more impact on the score. Conversely, in very large
ROI volumes, as CTV-node or bowel, it seems to lack the sensitivity to recognise divergences
from the reference contour (Figure 4.2) (Breunig et al., 2012; Esthappan et al., 2011). This
phenomenon is due to the duplication of the overlapping volume, which may falsely show
considerable agreement in these large ROI. But this index is very simple to calculate, making
it is the most used index in automatic segmentation studies (Hoang Duc et al., 2015). The
DICE index may also be converted into other overlap indexes by using certain ratios (Fotina
et al., 2012).
An ultimate limitation to performing a more exhaustive RTQA programme was trial
monitoring of the electronic case report forms (eCRFs) and the ﬁnancing allotted. Initial
plans were to perform a more complete RTQA assessment, including an ICR of the ﬁrst
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patient included and a patient chosen at random from each centre. This review would have
included the clinical case, delineation and treatment planning. Several diﬃculties were en-
countered. Firstly, centres had many diﬃculties ﬁlling in correctly the radiotherapy sections
of the eCRFs. They were slightly modiﬁed by the RAIDs RTQA group to improve their
comprehensibility, but due to coordination issues many of these modiﬁcations and speci-
ﬁcations were not incorporated into the eCRFs. Fortunately, the site visits performed by
the study monitors identiﬁed diﬀerent interpretations between centres of the radiotherapy
eCRFs, which helped improve the quality of this data, as evoked by Haworth et al., (2009).
This led to an extensive collaboration between the RAIDs RTQA group and the study mon-
itors to achieve accurate, interpretable radiotherapy data by the end of the 5 year RAIDs
project. Thus a real-time or even coetaneous ICR could not be performed. Secondly, as
previously mentioned, obtaining collaboration from radiotherapy professionals from partic-
ipating RAIDs centres proved complicated for the ODW and surely would have been even
more diﬃcult for an ICR. Lastly, the budget for RTQA covered the realisation and poste-
rior analysis of the contouring dummy run within the ODW, with no excess funding for the
creation of a server to import the diagnostic image sets, radiotherapy treatment image sets,
contours and plans.
These limitations are not unique to this study. Poortmans et al., (2006) have reported the
results from the dummy run and the ICR for the EORTC 22922/10925 addressing the role
of radiotherapy of the internal mammary and supraclavicular lymphatic chains. Forty-one of
the 45 participating institutes participated in the dummy run and only 20 (less than 50% of
those which completed the dummy run) did the ICR. The positive side is that the institutes
which completed the dummy run included 93% of the study patients, and those which did
the ICR included 76%. Thus, the most motivated centres in the study correctly followed
the RTQA programme (Poortmans et al., 2006). In the current study, the centres which
participated in the dummy run accrued 66% of all RAIDs patients. The RTQA programme of
the Japan Clinical Oncology Group (JCOG) 0202 study (cisplatin-etoposide versus cisplatin-
irinotecan in consolidation chemotherapy for early stage small cell lung cancer) consisted in
an ICR of all accrued patients, without a previous dummy run (Sanuki-Fujimoto et al., 2009).
They found a gradual reduction of unacceptable variations, which were mostly within the
ﬁrst 3 patients. Their explanation was the feedback to centres on protocol compliance,
especially considering that no dummy run was performed before patient accrual (Sanuki-
Fujimoto et al., 2009). This clearly highlights the paramount importance of performing
a dummy run, even when an exhaustive ICR is performed. Another Japanese publication
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presented the RTQA results of the ICR of the (JAROG0401/JROSG04-2) study in early
stage cervical cancer, aiming to evaluate the eﬃcacy and toxicity of radical EBRT followed
by high dose rate (HDR) BT (Toita et al., 2009). The BT was administered by a two-
dimensional (2D) technique, and 17% of the ICR showed a deviation of the protocol with
regard to the determination of the point A. The authors recognise this 2D technique is
outdated and manifest the need for a more stringent RTQA programme in future cervical
cancer trials, including a dummy run.
Budget issues for RTQA within multicentre trials have been well described in previous
publications. Thus several, in line with our study, have only performed a dummy run.
An example is the Barillot et al., (2014) study on postoperative IMRT for endometrial
cancer. Poortmans et al., (2005) state that the increasing complexity of RTQA programmes
due to modern radiotherapy techniques such as IMRT and SBRT convey a larger workload
and an increased cost. In the present study, both IMRT and image guided radiotherapy
(IGRT) could be used, as well as classic radiation techniques like 3D radiotherapy and two
dimensional BT.
5.7 Future perspectives
Several eﬀorts are being made to improve and homogenise RTQA programmes, so as
to reach the perfect balance between thoroughness and eﬃciency. As recently as 2014, the
National Clinical Trials Network (NCTN) has been created by the National Cancer Institute
(NCI) to coordinate all intergroup Phase III clinical trials. Within the NCTN a speciﬁc
group is in charge of imaging and RTQA: the Imaging and Radiation Oncology Core Group
(IROC) (Fitzgerald, 2013). The key role of IROC is to implement an eﬃcient and eﬀective
RTQA workﬂow, by integrating standard operating procedures for imaging and radiotherapy
dataset transfer, as well as providing initial site evaluations and credentialising, protocol
support, transfer of electronic data, data management and ICR (Fitzgerald, 2013). The goal
of IROC is to streamline the process, allowing for a uniform and rigorous RTQA programme
across the NCTN (Fitzgerald, 2013).
Within the EORTC much of the aforementioned processes may be performed using the
Visualization and Organization of Data for Cancer Analysis (VODCA) system (Weber et al.,
2011). This system even creates dose-response models, allowing evaluation of the relationship
between results and RTQA compliance in trials. This is essential to present the validity of
these results in light of high quality radiotherapy (Weber et al., 2011).
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Future directions in RTQA must incorporate common RTQA baseline centre credential-
ising, allowing centres participating in several trials to submit only speciﬁc credentialising
data for each trial, thus decreasing their workload (Miles and Venables, 2012). This will also
permit eﬀorts to be centred on audits and updating of the status of the trial centres (Miles
and Venables, 2012).
Two multicentre trials considered the main RTQA method should be the dummy run, and
not a prospective interventional ICR of all patients (Fairchild et al., 2012a). In the TROG
0202 head and neck study they felt that the latter could not rectify planning deviations
within an acceptable timeframe (L. J. Peters et al., 2010). In the case of the EORTC 20884
lymphoma study they believed the workload was too cumbersome (Aleman et al., 2005).
Clearly, automatising of ICR within a digital platform such as VODCA allowing for real-
time case reviewing may change these conclusions. Innovative approaches to automating
RTQA include a pilot study applying a knowledge base built from nine delineations from 29
head and neck cancer treatment plans (Altman et al., 2015). The base calculated several
metrics from the plans, such as the shape, size, position in relation to other structures,
etc. and determined heuristically derived rules. They analysed nine more plans with 42
contouring errors, and the knowledge base identiﬁed 40 of these errors, along with 9 false
positive results (Altman et al., 2015). Potentially, this could be applied within digital RTQA
platforms.
A ﬁnal perspective to be performed within the scope of this thesis will be an analysis of
the eCRFs to correlate the RT treatments administered with morbidity and response. It will
also allow for a general description of RT practices within diﬀerent European centres. As
previously mentioned, curated eCRFs data has only become available in late 2017, thus this
will be performed during the following months. Depending on the quality of the eCRFs data,
either an initial analysis will be performed presenting local control and acute morbidity, fol-
lowed by a second analysis evaluating long term local control, survival and chronic morbidity,
or if long term follow up data is unavailable, only the ﬁrst analysis will be possible. The
data in the eCRFs include the overall treatment time, and if it exceeds 55 days its possible
impact on local control shall be evaluated (Haie-Meder et al., 2010b; Tanderup et al., 2016).
Unfortunately these issues are not infrequent, an example is Fairchild et al., (2012c). In
that study on low grade glioma, case report forms often were incomplete or contradicted the
results of the digital review. Since unfortunately in this study a digital review of the cases
was not performed, the monitoring of the eCRFs data is relied upon.
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1. En general, se observó sobre todo una mejoría signiﬁcativa en la variabilidad interob-
servadora e intraobservadora cuantitativa entre contornos guía (C2) y basales (C1) para los
dos tratamientos, y la única diferencia cualitativa notable fue una mejoría de la delineación
de volúmenes blanco entre estos periodos para braquiterapia (BQT).
2. Los resultados del cuestionario de satisfacción han dejado patente que los participantes
consideran la metodología de enseñanza del taller de delineación en línea (TDE) muy apta.
3. El análisis cuantitativo de la variabilidad interobservadora entre los centros que usan
de manera rutinaria la resonancia magnética para la delineación de tratamientos de BQT
y los que no, mostró mejores resultados en contorneo del high risk CTV (HR-CTV) en los
centros acostumbrados a esta técnica.
Concluimos que el TDE ha sido validado para el asesoramiento inicial de la delineación
en centros geográﬁcamente distantes, permitiendo un control de calidad inicial de un ensayo
multicéntrico en cáncer de cérvix localmente avanzado (CCLA), asimismo ofreciendo una
formación inicial en delineación. Sin embargo, en el futuro los esfuerzos deben dirigirse a
mejorar esta formación, especialmente en cuanto al efecto de la enseñanza a largo plazo
(contornos ﬁnales (C3)). Los centros con participantes que necesitan mejorar deben tener la
posibilidad de continuar formándose, siguiendo una secuencia óptima de métodos en línea,
en persona o una combinación de ambos.
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1. Overall, there was mostly a signiﬁcant improvement for quantitave interobserver and
intraobserver variability between guideline contouring (C2) and baseline contouring (C1) for
both treatments, and the only notable qualitative diﬀerence was an improvement in target
volume (TV) delineation between these periods for brachytherapy (BT).
2. The results of the satisfaction questionnaire have clearly proven that participants
highly appreciate the teaching methodology of the online delineation workshop (ODW).
3. The quantitative analysis of the interobserver variation between centres using magnetic
resonance imaging (MRI) routinely for BT planning and those that do not showed better
performance in contouring for the HR-CTV for centres accustomed to this technique.
Thus, the ODW has been validated for initial assessment of delineation in geographically
distant centres, allowing baseline quality control for a multicentre trial in locally advanced
cervical cancer (LACC), as well as oﬀering initial training in delineation. However, future
directions should insist on improvement of this training, especially with respect to the long
term teaching eﬀect (ﬁnal contouring (C3)). Centres with participants requiring improve-
ment should be oﬀered further training, following the optimal sequence of online, onsite or
blended approaches.
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Background and purpose: Online delineation workshops (ODW) permit training of geographically dis-
persed participants. The purpose is to evaluate the methodology of an ODW using FALCON to harmonize
delineation within a European multicentre trial on locally advanced cervical cancer (LACC).
Material and methods: Two ODW included 46 clinicians (14 centres). Clinicians completed baseline (C1),
guideline (C2) and final contours (C3) for external beam radiotherapy (EBRT) and brachytherapy (BT) for
LACC. Interobserver and intraobserver variability was evaluated quantitatively (using the DICE index) and
qualitatively compared to expert contours.
Results: Nine clinicians submitted for EBRT and BT for C1–C3. Thirty-two sent any contour. Interobserver
quantitative comparisons for EBRT showed significant improvement for C2 vs. C1 for bowel, CTV node,
CTV-p and GTV node with significant detriment for GTV node (C3 vs. C1; C2), CTV-p (C3 vs. C2) and bowel
(C3 vs. C2), showing in general an improvement in C2 vs. C1, with a detriment in C3 vs. C2 for two target
volumes and an organ at risk. For BT there was significant improvement for C2 vs. C1 for bladder, GTV,
HR-CTV and IR-CTV, with significant detriment for bladder (C3 vs. C2), thus overall improvement in C2
vs. C1, with only a detriment in C3 vs. C2 for bladder. Centres using MRI imaging for BT contouring
did significantly better in the BT case for HR-CTV than those which used other techniques (C2 vs. C1:
p < 0.005; C3 vs. C1: p = 0.02). Intraobserver quantitative comparisons showed significant improvement
contouring a region of interest between C2 vs. C1, C3 vs. C1 and C3 vs. C2 for EBRT and between C2
and C1 for BT.
Conclusions: ODW offer training, initial contouring harmonization and allow assessment of centres.
 2017 Elsevier B.V. All rights reserved. Radiotherapy and Oncology 124 (2017) 130–138
Much has evolved since the first contouring dummy run includ-
ing distant centres within a multicentre trial, which used CT hard
copies [1]. As described in 1995, online education allows participa-
tive medical training for geographically dispersed students [2].
Flexibility, essential within e-learning, especially for medical pro-
fessionals, defined as ‘learner control’, offers self-task management
[3]. Student outcome evaluation is also important, though few
report objective internal testing to validate web-based learning
tools as a primary outcome [4–7].
Radiotherapy quality assurance has become key to ensure inter-
pretable results within multicentre trials, especially after reports
have shown the influence of contouring on patient outcomes [8–
11]. Hence the phase III trial of concurrent cisplatin and tirapaza-
mine in head and neck cancer in which when radiotherapy compli-
ance was analysed, a significant reduction of 2 year overall survival
and locoregional control was observed when treatment plans were
largely deviated from protocol [8].
Proper delineation of target volumes (TV) and organs at risk
(OAR) is crucial, allowing optimal oncological treatment and better
knowledge of the dose received by surrounding healthy tissue.
Thus, several studies have evaluated interobserver and sometimes
intraobserver variability between contours [12–15]. Two recent
http://dx.doi.org/10.1016/j.radonc.2017.05.008
0167-8140/ 2017 Elsevier B.V. All rights reserved.
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reviews addressed this issue, one proposing reporting items for
these studies, which this paper will adhere to [16,17]. In locally
advanced cervical cancer (LACC) this variability acquires even
higher significance. Recent advances in External Beam Radiother-
apy (EBRT) and Brachytherapy (BT), namely image guided
brachytherapy (IGBT), have shown 3 year local control rates of
92% (tumours > 5 cm) and 98% (tumours 2–5 cm) [18]. This was
achieved by applying the Gynaecological GEC-ESTRO (Groupe Eur-
opéen de Curiethérapie – European Society for Radiotherapy &
Oncology) recommendations to the high risk clinical TV (HR-CTV)
and dose volume constraints for OAR [19].
The purpose of this study is to validate the methodology of an
online delineation workshop (ODW) within a European multicen-
tre prospective study in LACC (Rational molecular Assessments
and Innovative Drug Selection: RAIDs), which includes 22 Euro-
pean clinical centres including Eastern and Western Europe [20].
To this aim, participant contours in different periods were
reviewed, as well as the participants’ personal perception of the
knowledge acquired.
Materials and methods
Before the ODW a general questionnaire about LACC radiother-
apy was sent to RAIDs centres for input on their practice (Table 1).
ODW structure
Two to four participants from each centre (proportional to the
gynaecological team) were enroled in an ODW in LACC, exceeding
its capacity, thus two ODW were planned. A technical partnership
was established with ESTRO. The methodology was similar to that
used in FALCON (Fellowship in Anatomical deLineation and
CONtouring) ESTRO ODW [21]. Live presentations were via WebEx
and contouring was done using the FALCON EduCaseTM contouring
platform.
Training was given by an expert, CHM, with one tutor per
10 clinicians. Tutors were radiation oncologists with experience
in LACC, trained to use FALCON EduCaseTM. Live sessions were
completed in 3 weeks and participants delineated EBRT (on
Computed Tomography: CT) and subsequent BT (on Magnetic
Resonance Imaging: MRI) image sets for the same clinical case.
The case and image sets with expert contours were chosen
with CHM, from the ESTRO FALCON EduCaseTM contouring
library.
The ODW were held on June–July 2013 and January 2014,
respectively, with an identical structure. The first two live sessions
were presented by tutors.
– Session 1 exposed FALCON EduCaseTM and the clinical case. Par-
ticipants were informed (orally and in writing) that their con-
tours would be in a study evaluating the ODW, requesting
their conformity, which was not revoked. Clinicians had 6 days
for baseline contouring (C1, reflecting daily practice).
– Session 2 presented contouring guidelines for EBRT and BT
based on the EMBRACE (An intErnational study on MRI guided
BRachytherapy in locally Advanced CErvical cancer) protocol,
reviewed baseline contours, and included a question-and-
answer session. Recommendations from the Gynaecological
GEC-ESTRO working group, EMBRACE protocol, a pelvic nodal
atlas and two consensus atlases for pelvic normal tissue were
sent to clinicians to aid delineation [19,22–25]. They had
2 weeks to modify contours for the same image sets (guideline
contouring: C2).
– In session 3 CHM reviewed baseline and guideline contours and
held a question-and-answer session.
Lastly, clinicians performed final contouring (C3) for EBRT and
BT 1.5–2 months after session 3, to evaluate the long term teaching
impact.
Clinical case
A forty-five year old patient with a FIGO IIIB squamous cell CC
was studied. Gynaecological exam: large growth (85x50x60 mm)
involving the vagina (all fornices 1 cm, anterior vaginal wall
4 cm). The right parametrium had proximal infiltration, the left
one until pelvic side wall. Bladder mucosa was not involved. Abdo-
minopelvic CT showed CC with vaginal involvement, enlarged
external, internal, lower common iliac, and pre-sacral nodes. No
paraaortic nodes. The response to EBRT and concomitant
chemotherapy was good: tumour dimensions of 55x40x30 mm,
free right parametrium, induration of half of the left parametrium,
and involvement of 1 cm of the anterior vaginal wall at the time of
BT.
– Volumes required for contouring exercises (at least specified
slices for OAR and whole ROI for TV):
 EBRT:
s OAR: Bladder, rectum, bowel, sigmoid.
s GTV-P (gross tumour volume-P): Cervix, parametria and
vaginal gross disease.
s CTV-nodes: Nodal elective volume.
s GTV node: Radiologically pathological lymph nodes (to
boost).
s CTV-P: GTV-P, uterus and vagina (20 mm below GTV-P).
 BT:
s OAR: Bladder, rectum, sigmoid.
s GTV: Macroscopic tumour at BT.
s HR-CTV: Macroscopic tumour at BT + whole cervix + pre-
sumed extra-cervical tumour extension.
s IR-CTV (intermediate risk CTV): HR CTV + GTV at diagno-
sis + 10 mm margin to residual disease at time of
brachytherapy towards potential spread.
Contour evaluation methodology
Intraobserver variability was evaluated between C2 vs. C1, C3
vs. C2 and C3 vs. C1, for EBRT and BT treatments, quantitatively
and qualitatively.
Interobserver variability was determined quantitatively by
analyses centred on regions of interest (ROI) and on years of expe-
rience, and for BT also between centres that used MRI-based IGBT
and others.
Contours were quantitatively classified by DICE scores
[DICE = 2  (Volumeexpert \ Volumeparticipant)/(Volumeexpert + Vol-
umeparticipant)] given by FALCON EduCaseTM Output [26]:
DICE references for TV [27,28]:
A: Optimal: >0.81
B: Average: 0.65–0.81
C: Suboptimal: <0.65
DICE references for OAR [29]:
A: Optimal: >0.81
B: Suboptimal: 0.81
In MRI-based brachytherapy for cervical cancer, Dimopoulos
et al. defined a range of 0.5–0.7 using the conformity index for tar-
get volumes, which when converted to DICE is roughly 62.5–0.81
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[27,30]. For OAR, Breunig et al. found an average DICE of 0.61 for
volumes <8 cc and of 0.91 for volumes >8 cc, averaging at 0.76
[29]. To simplify the cutoffs and make the study easier to interpret,
0.65 and 0.81 were chosen for TV and 0.81 for OARs. Of note, all
statistical analyses performed were independent of the thresholds
that were only used to aid interpretation and to display the results.
For the objective qualitative intraobserver assessment, the
EduCaseTM contour error distance tool showed on axial slices where
the participant contour was 3 mm larger or smaller than the expert
contour, based on the scalar assessment in the transverse plane for
HR-CTV by Petric et al., in 8 directions (anterior, posterior, right,
left, anterolateral right and left and posterolateral right and left)
to detect the most prevalent areas of uncertainties [13].
Qualitative Classification:
– ‘‘Correct”: Participant contour 3 mm smaller/larger than the
expert contour in a given direction.
– ‘‘Incorrect”: Participant contour >3 mm smaller/larger than the
expert contour in a given direction without a probable clinical
impact.
– ‘‘Very incorrect”: Participant contour >3 mm smaller/larger
than the expert contour in a certain direction which for that
particular ROI will have a probable clinical impact (worse cov-
erage of TV/ higher dose to OAR).
As part of the outcome of e-learning courses depends on partic-
ipant perception, an anonymous satisfaction questionnaire
adapted from FALCON-ESTRO ODW was administered to clinicians
(Appendix 3).
Statistical analyses
DICE scores have been transformed using the logit function,
logit(x)=x/(1-x), so they asymptotically follow a Gaussian distribu-
tion [31,32].
To assess interobserver variability, a linear mixed model (Mod-
elINTER.PART)was used, with the fixed effects ROI, contouring per-
iod, experience, their interactions, the linear and quadratic effects of
the slice and their interactions with the ROI (for BT: the effect imag-
ing technique and the interaction ROI*imaging technique was
added), and the random effect of interparticipant variability, con-
sidered different for OAR and TV. To assess intraobserver variabil-
ity (difference of DICE scores between contouring periods), a paired
comparison by participant and ROI was performed using a linear
model (modelINTRA.PART) with the fixed effect participant, ROI
and their interaction (participant*ROI). The average DICE score by
participant and ROI for each contouring period was assessed by a
similar model (modelSCORE.PART). The significance of the fixed
effects was computed using Fisher’s test for all models. The propor-
tion of pairs participant*ROI declared as performing better (or
worse) from modelINTRA.PART, and their association with other
covariates (experience, ROI type, institution or imaging technique)
were assessed with Fisher’s exact test. For the qualitative analysis,
to compare the proportions of correct contours between different
contouring periods, we used the test of McNemar [33]. The statis-
tical analysis was performed using R software (R Core Team, 2016)
and can be automatically reproduced using the scripts and data in
Supplementary information.
Results
Participant population
Participants from 14 of 22 RAIDs centres submitted contours
(Table 1).
Of the 46 enroled participants, nine submitted delineations for
all contouring periods for EBRT and BT (Table 2). The description
by level of experience of the participant population which submit-
ted contours is in Table 2.
There is no significant relationship between the participants
who dropped out after C1 with the initial DICE scores on C1
(whether they were low or high) nor with the years of experience
or centre (Appendix 1: Tables 26–28; Appendix 2: Tables 29–31).
The adequacy of the cutoff points for this study was confirmed
by the distribution of the pooled data (for EBRT and BT over all con-
touring attempts). The first quartile for OAR is 0.8 and for TV the
first quartile is 0.6 and the third quartile is 0.86, which is mostly
consistent with the chosen cutoff points (0.65 and 0.81).
All of the results of all models per contouring period are sum-
marized in Table 3.
Results of ModelINTER.PART (interobserver variability)
All interactions were highly significant (p < 0.001), all effects
had an impact on DICE scores (Table 2 in Appendix 1, 2). The model
captures the quadratic relationship between DICE score and slice
number (Fig. 1).
Pairwise comparisons for EBRT and BT between contouring
periods by ROI are reported in Table 2 (details in Appendices 1–
2, Table 5). For both EBRT and BT in C2 vs. C1 there was a signifi-
cant improvement, mostly for TV, with no significant decrease.
For C3 vs. C1 in EBRT and BT there was also a significant increase
observed in certain TV with only a significant decrease for GTV
node. However, in C3 vs. C2 for both image sets there was a signif-
icant decrease for 2 TV in EBRT and 2 OAR (no decrease for TV in
BT), with a significant increase for CTV node.
For EBRT (Appendix 1, Table 6), regarding the experience effect,
experienced specialists performed significantly better than junior
Table 2
Participants enroled in the online delineation workshops which submitted contours for each contouring period.
EBRT BT
C1 C2 C3 C1 C2 C3
Submission of  1 contour 28 22 13 30 21 13
Submission of all contours (OAR and TV) 14 11 5 24 15 6
Submission of only TV 19 15 7 24 15 9
Total number of participants (n) 46 46
PARTICIPANT POPULATION WHICH SUBMITTED CONTOURS
Experienced specialists (>5 years of post-residency experience) 13
Less experienced specialists (5 years of post-residency experience) 8
Senior residents (>2 years of experience) 7
Junior residents (2 years of experience) 4
The participant population which submitted contours, by level of experience.
Abbreviations: EBRT: External beam radiotherapy; BT: Brachytherapy; OAR: Organs at risk; TV: Target Volumes.
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Fig. 1. Means of DICE scores (1 indicating perfect concordance between participant and expert; 0 indicating no concordance) by ROI according to slice number. The lines
represent the mean of the DICE score predicted by the mixed model, capturing the parabolic effect of the slice number on the DICE scores. (a) Means of DICE scores by ROI
according to slice number for EBRT. (b) Means of DICE scores by ROI according to slice number for BT.
Fig. 2. (a) The interaction ROI*imaging technique in the BT treatment for centres using MRI-IGBT (black) and those not using it (light grey) (ModelINTER.PART). (b) Baseline
contours (C1) of GTV for centres using MRI-IGBT (dark grey) and those not using it (white). Expert contour in black, with diagonal lines.
Fig. 3. The average score for each participant and each ROI for the C2 (x-axis) and C1 (y-axis) for (a) EBRT and (b) BT estimated from themodelSCORE.PART and whether the
delineation improved or not (the difference is significantly better, equal or worse, frommodelINTRA.PART, intraobserver variability). Examples (Ex.): Ex. 1.: This participant’s
DICE index did not vary significantly (same) between C2 vs. C1 for GTV, staying within the suboptimal category. Ex. 2.: This participant’s DICE index was in significant
detriment (worse) between C2 vs. C1 for rectum, changing from the optimal to the average category. Ex. 3.: This participant’s DICE index improved significantly (better)
between C2 vs. C1 for IR-CTV, changing from the average to the optimal category.
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residents for sigmoid and significantly worse than less experienced
specialists and senior residents for GTV node and than junior resi-
dents for GTV-p. Less experienced specialists did significantly bet-
ter than junior residents for GTV node and sigmoid, and than senior
residents for sigmoid. Between senior and junior residents there
were only significant differences for GTV node and GTV-p. For BT
the only significant difference was that experienced specialists per-
formed better than senior residents for sigmoid (Table 3; Appendix
2, Table 6).
Regarding the imaging technique, centres that used MRI based
IGBT did significantly better than those which used other tech-
niques (CT, X-ray, US) for HR-CTV (Fig. 2, Table 3).
The ICC (intraclass correlation) for interobserver variability was
excellent for OAR in BT (0.92; 95% CI: 0.86–0.96), OAR in EBRT
(0.96; 95% CI: 0.93–0.98) and TV in EBRT (0.78–95% CI: 0.68–
0.88) while it was fair for TV in BT (0.51; 95% CI: 0.39–0.68) (Table 4
in Appendix 1, 2). The low ICC for TV in BT highlights the difficulty
of participants to agree on contours, whether they usually contour
on MRI or not (the imaging technique was taken into account in
modelINTER.PART).
Results of modelINTRA.PART and modelSCORE.PART (intraobserver
variability)
Fig. 3 (Fig. 7, Appendixes 1 and 2) represents the average score
for each participant and each ROI for C2 and C1 for EBRT and BT
estimated from the modelSCORE.PART and whether the differ-
ence is significantly better, equal or is worse (from modelIN-
TRA.PART). The Fisher’s exact tests show that participants
improved significantly between all contouring periods for EBRT
(Appendix 1: Tables 8, 13 and 18). For BT, participants improved
significantly between C2 vs. C1 (Appendix 2, Table 8). For EBRT,
the improvements were significantly associated to ROI.type (TV
vs. OAR) and institutions (C2 vs. C1). For BT, the improvements
are significantly associated to ROI.type between C2 vs. C1
(Table 3). Interestingly, the number of participants who per-
formed worse between different contouring periods was never
significant (Fisher’s exact test).
Results of qualitative data (intraobserver variability)
For EBRT, the percentage of ‘‘correct” contours was only signif-
icantly better between C2 vs. C1 for posterolateral right in TV. It
was significantly worse in TV for anterolateral right for C3 vs. C2
and in three directions for C3 vs. C2 (Table 3; Appendix 1, Fig. 15).
For BT, the percentage of ‘‘correct” contours was significantly
better between C2 vs. C1 for posterolateral right and right in TV
and between C3 vs. C1 for posterolateral right in OAR. It only
was significantly worse between C3 vs. C1 and C2 for posterolat-
eral right in TV (Table 3; Appendix 2, Fig. 15).
Results of the satisfaction questionnaire
The scores over the 20 Organization and Content items for the
20 participants who responded of the 32 that submitted contours,
on a scale of 1–5, 5 being excellent, range from 3.95 to 4.60 with an
average of 4.358 (Table 3, Appendix 3). When asked whether they
would attend another online workshop, 80% of participants
answered affirmatively, and 85% would recommend one.
Discussion
For the first time this recent modality of ODW has been used
for assessment of contouring skills as a dummy run within a mul-
ticentre trial [21]. Recently, other trials have used ODW within
their quality assurance programmes, such as HYPO-G-01 [34].
Other authors, like Fokas et al., advocated training programmes
within radiotherapy quality assurance protocols [35]. Our results
have shown the ODW feasibility and capability in identifying cen-
tres that manifest baseline and subsequent average to optimal
contours and are ready to include patients, while offering an
effective educational tool for others. The added value of this study
is that it reports the participants’ point of view, which in light of
the post-ODW satisfaction questionnaire results is extremely
favourable.
Petric et al. have described graphically how the largest
uncertainties in contouring are on the cranial and caudal slices of
a volume, which coincides with our results (Fig. 1; Fig. 5
Appendixes 1 and 2) [15]. The bowel follows a particular pattern
since the expert contour consisted of individual bowel loops and
most participants contoured a bowel bag, but both contouring
techniques are valid [36].
An interesting aspect of this study is that the evaluation of
interobserver variability allowed assessment of overall improve-
ment/detriment of the participants in the workshop group
between them, and not only individual variability versus the
expert contour (which affects the comparison of ROI, and has cer-
tain flaws) [16,37]. As could be expected, for interobserver compar-
isons in both EBRT and BT, there was overall more improvement
between C2 and C1 than between C3 and C1, and the worse results
were mostly between C3 and C2. This suggests that participants
gained contouring skills after presentation of the guidelines, and
retained part of this knowledge 1.5–2 months later. However, from
the intraobserver point of view, only improvements were signifi-
cant between contouring periods.
When considering interobserver variability with respect to
experience in EBRT, experienced specialists did significantly worse
than less experienced specialists and senior residents for GTV
node. This finding is to be interpreted with caution, as there was
a borderline significant paraaortic lymph node (though the clinical
case states: ‘no positive paraaortic lymph nodes’) and a suspicious
lymph node in the left groin, deemed as inflammatory by CHM
during live sessions. Thus this may simply highlight that less expe-
rienced specialists and senior residents were more focused on the
clinical information provided. Logically, less experienced special-
ists, with more experience, did better than junior residents for
GTV node and than junior and senior residents for sigmoid, as
senior residents did better than junior residents for GTV node (all
significant). Surprisingly, junior residents did significantly better
than senior residents for GTV-p. For BT the only significant differ-
ence was experienced specialists which contoured the sigmoid bet-
ter than senior residents.
Concerning MRI guided IGBT, MRI allows better visualization
of the vagina and uterus than of the rectum or bladder [38]. This
may explain our results of interobserver improvement in HR-CTV
and IR-CTV for C2 and C3 vs. C1, as opposed to a detriment for
the bladder (C3 vs. C2). It is also interesting to note the significant
improvement for contouring of HR-CTV for centres doing MRI-
IGBT, showing the impact of specific training in MRI-based
contouring.
Qualitatively, Petric et al. did not find significant interobserver
differences along the 8 directions of space for HR-CTV contours
[13]. Our intraobserver differences were significant for certain
directions (better or worse) for EBRT, with no obvious explanation
as there was no clear clinical impact due to these differences. How-
ever, for BT, the significant improvement towards the right and
posterolateral right for TV in C2 vs. C1 most probably is because
the left parametrial invasion made participants focus more on
the left portion of the TV than on the right during C1, and they
improved after the guideline session. But they went back to their
old ways in C3, doing significantly worse for posterolateral right
TV in C3 vs. C1 and C2.
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Considering the e-learning educational experience, this ODW
allows a self-directed path, each clinician may attend live online
sessions, within a blended learning model (with support and inter-
action with tutors) or follow recordings. This flexibility adapted to
the physicians’ heavy workload [3]. But this was not always effec-
tive, 14 of the initial 46 enroled participants did not submit
contours.
Initial limitations of this study were organizational: difficul-
ties to locate radiotherapy professionals, as the ODW was per-
formed before opening RAIDs in clinical centres. Further, the
first ODW was held in June–July. Many clinicians could not par-
ticipate, or only could attend some sessions, with fewer contour
sets submitted during July (C2), and August–September (C3).
Thus, only 13 contours were submitted for C3, limiting statisti-
cal significance and with a less representative population.
Another limitation was the use of the DICE index, the only con-
touring conformity index available as FALCON EduCaseTM output
at the time. It is less reliable in small ROI volumes, such as GTV
node, GTV or sigmoid in our study, showing lower concordance
simply because slight delineation discrepancies have more
impact on the score. Conversely, in very large ROI volumes, as
CTV node or bowel, it seems to lack the sensitivity to identify
divergences from the reference contour (Fig. 1) [29,39]. This is
due to the duplication of the overlapping volume, which may
inaccurately show considerable agreement in these large ROI.
The strongpoint of this index is the simplicity of calculation,
it is the most used in automatic segmentation studies [40]. It
may also be converted into other concordance indexes using
certain ratios [30].
In conclusion, ODW provide feasible and convenient means for
initial assessment of contouring practices in geographically dis-
persed centres, as well as additional training in contouring within
the setting of quality control for a multicentre trial. Future studies
should focus on improving this training, and developing the opti-
mal sequence of further training for centres which need more
improvement (further online training, or combined with specific
onsite programmes).
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Techical partnership with:                                                         
 
 
ONLINE CONTOURING WORKSHOP ON ADVANCED STAGE CERVICAL CANCER  
June 20th and 26th and July 10th, 2013 
 
We hope that you have found this workshop useful, but since nothing is perfect, we need your 
evaluation to continue to develop this workshop to meet participants’ needs. We therefore kindly ask 
you to fill this in and send it back to us. Thank you for your co-operation. 
 
I  BACKGROUND INFORMATION: 
 
1.  Gender:   □ Male   □ Female  
 
     I am working in ……………………………….(country)   
 
2. Specialty: 
 
I am a (  )  Radiation oncologist    (  ) Specialist   (  ) Trainee 
(  )  Other_________________________________________________________ 
 
Number of years working in the specialty_____ 
 
3. I learned about this workshop from: 
 
(  ) RAIDs project manager (M. Kamal) and/ or 
WP-4.2 leader IGR (C.Haie-Meder,E.Deutsch,E.Rivin)      
(  )  Department director                
(  )  Colleagues                                 
 
4.  I have previously attended the following ESTRO events:  
 
(   )   ESTRO teaching course(s) 
(   )   ESTRO meeting(s) 
(   )   ESTRO on-line course(s) 
(   )   ESTRO contouring workshop(s) 
 
 (   )   ESO courses 
 (   )   Other courses 
 (   )   Other contouring workshop(s) 
 
 
 
5. Do you perform contouring in cervical cancer? 
 
     Never 
 Sometimes – please specify:...................................................   
 Yes, for External Beam Radiotherapy under supervision 
      Yes, for External Beam Radiotherapy without supervision 
 Yes, for Brachytherapy under supervision 
     Yes, for Brachytherapy without supervision 
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6. Do you have experience with contouring in: 
 
     CT-images only 
 MRI images only 
 Matched CT and MRI images 
 PET-images 
 Multimodality (PET-CT-MRI) 
      Ultrasound images 
 
II. ORGANISATION and EDUCATIONAL MATTERS 
 
Grading scale:   (5) = Excellent     (4) = Good      (3) = Average      (2) = Sufficient   (1) = Poor 
 
7. The goals of this workshop were clearly stated at the beginning   (     ) 
…………………………………………………………………………………………………………………………………………………..… 
…………………………………………………………………………………………………………………………………………………..… 
8. The supplementary material was         (     ) 
…………………………………………………………………………………………………………………………………………………..… 
…………………………………………………………………………………………………………………………………………………..… 
9. The Webex platform for the live presentations was     (     ) 
…………………………………………………………………………………………………………………………………………………..… 
…………………………………………………………………………………………………………………………………………………..… 
10. The Falcon-Educase contouring tool was       (     ) 
…………………………………………………………………………………………………………………………………………………..… 
…………………………………………………………………………………………………………………………………………………..… 
11. The workload demands were realistic for this workshop    (     ) 
…………………………………………………………………………………………………………………………………………………..… 
…………………………………………………………………………………………………………………………………………………..… 
12. The experts’ presentation was         (     ) 
…………………………………………………………………………………………………………………………………………………..… 
…………………………………………………………………………………………………………………………………………………..… 
13. The discussion by the experts and the tutors was     (     ) 
…………………………………………………………………………………………………………………………………………………..… 
…………………………………………………………………………………………………………………………………………………..… 
14. The language used was clear and understandable and facilitated interaction  (     ) 
…………………………………………………………………………………………………………………………………………………..… 
…………………………………………………………………………………………………………………………………………………..… 
15. The experts and tutors continuously encouraged communication   (     ) 
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…………………………………………………………………………………………………………………………………………………..… 
…………………………………………………………………………………………………………………………………………………..… 
 
16. The support from ESTRO and tutors for the delineation exercise was    (     ) 
…………………………………………………………………………………………………………………………………………………..… 
…………………………………………………………………………………………………………………………………………………..… 
17. The learning experience was equivalent to the experience in face-to-face workshops (     ) 
…………………………………………………………………………………………………………………………………………………..… 
…………………………………………………………………………………………………………………………………………………..… 
18. The workshop met my expectations       (     ) 
…………………………………………………………………………………………………………………………………………………..… 
…………………………………………………………………………………………………………………………………………………..… 
19. Other comments:  
…………………………………………………………………………………………………………………………………………………..… 
…………………………………………………………………………………………………………………………………………………..… 
…………………………………………………………………………………………………………………………………………………..… 
…………………………………………………………………………………………………………………………………………………… 
 
III.   CONTENTS OF THE WORKSHOP 
Grading scale:   (5) = Excellent     (4) = Good     (3) = Average     (2) = Sufficient     (1) = Poor 
 
 
General  
 
Please, circle the digit of your 
choice on the scales below. 
1.  Did the workshop provide the following goals and 
learning outcomes: 
 
 The workshop should allow the participants to obtain a 
thorough understanding of the contouring guidelines in 
cervical cancer. 
 
1        2        3        4       5 
no --------relatively------ yes 
 
 
The workshop should allow the participants to obtain a 
good knowledge of contouring in cervical cancer and 
useful imaging modalities to do so.  
 
 
1        2        3        4       5 
no --------relatively------ yes 
 
 
The workshop should allow the participants to improve 
their contouring skills  
 
1        2        3        4       5 
no --------relatively------ yes 
 
 
2. Please, provide your overall rating of the quality of the education offered at this workshop. 
 
1        2        3        4       5 
poor ----------------excellent 
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Content  
 
3.  
 
Was the information useful and relevant to your work 
and practice techniques? 
 
1        2        3        4       5 
no ------------------------- yes 
 
 
4. 
 
Do you feel that the presented information was well 
balanced and supported by adequate evidence? 
 
 
1        2        3        4       5 
no ------------------------- yes 
 
5. 
 
Did the programme allow adequate time for discussion 
and questions? 
 
 
1        2        3        4       5 
no ------------------------- yes 
Organization  
 
6. 
 
How would you rate the management and organization 
of this workshop? 
 
 
1        2        3        4       5 
poor ----------------excellent 
 
IV.   GENERAL CONCLUSION: 
 
What topics would you like to be added to the on-line contouring workshops? 
……………………...………………………………………………………………………………………………………………………...…… 
……………………...………………………………………………………………………………………………………………………...…… 
……………………...………………………………………………………………………………………………………………………...…… 
 
Any special comments: 
……………………...………………………………………………………………………………………………………………………...…… 
……………………...………………………………………………………………………………………………………………………...…… 
……………………...………………………………………………………………………………………………………………………...…… 
 
Would you be interested in attending another on-line contouring workshop? 
……………………...………………………………………………………………………………………………………………………...…… 
……………………...………………………………………………………………………………………………………………………...…… 
……………………...………………………………………………………………………………………………………………………...…… 
 
Would you recommend an on-line contouring workshop? 
……………………...………………………………………………………………………………………………………………………...…… 
……………………...………………………………………………………………………………………………………………………...…… 
……………………...………………………………………………………………………………………………………………………...……
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8.3 Curriculum vitæ
8.3.1 Education
1999-2006 M.D. in Medicine and Surgery. University of Malaga; Malaga, Spain.
2008-2012 Specialty in Radiation Oncology. Reina Soﬁa University Hospital; Cordoba, Spain.
2008-2011 European Master's degree in Nutrition and Metabolism (Thesis: Nutritional Evalua-
tion in Cancer Patients before and after RT). University of Cordoba; Córdoba, Spain.
2012-2013 European Diploma in Clinical and Translational Research in OncologyD.U.E.R.T.E.C.C.
Gustave Roussy Cancer Campus  Paris Sud University; Paris, France.
2013  European Doctorate in Biomedicine. (Thesis project: Radiotherapy Quality Control
in Cervical Cancer.) University of Cordoba, Radiology and Oncology group.
8.3.2 Work experience
2008 2012 Reina Soﬁa University Hospital, Department of Radiation Oncology; Cordoba, Spain.
Residency in Radiation Oncology.
• 2011(March-May) Rotation in Brachytherapy. Valencian Oncology Institute; Va-
lencia, Spain.
• 2011(November-December) Observer rotation in SBRT (Cyberknife). Collabora-
tor. University of California at San Francisco; San Francisco, United States.
2012 Elche General University Hospital. ERESA. Department of Radiation Oncology; Elche,
Spain. Specialist in Radiation Oncology.
• Experience in every subspecialty with emphasis in breast and gynaecological can-
cer.
2013-2017 Gustave Roussy Cancer Campus Grand Paris. Department of Radiation Oncology 
Group A; Villejuif, France. Specialist in Radiation Oncology.
• Subspecialties: Breast cancer. Standard treatment (classic and hypofractionated
schedules) or accelerated partial breast irradiation (APBI) pre or postoperatively
in clinical trials. Gastrointestinal cancer. Standard treatment. Liver and pancre-
atic SBRT.
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2017 Tenon University Hospital. Department of Radiation Oncology. Specialist in Radiation
Oncology.
• Subspecialties: Breast, lung, gastrointestinal and prostate cancer.
8.3.3 Clinical trials experience
2008-2011 Design of the protocol: Nutritional evaluation before and after radiotherapy, its imple-
mentation, statistics, and writing for my master's thesis.
2012 Quality assurance of radiochemotherapy in cervical cancer in a european trial. Writing
of a randomised Ph. II-III trial: antiviral agent + RTCT in advanced cervical cancer.
2014 Co-investigator in my center in: PAPBI, SHARE, BONBIS, PRAVACUR and RAIDs.
2017 PI of the EORTC Ph. IV trial validating the ANL-27 QofL questionnaire.
2016-2017 Real time radiotherapy quality assurance for NBTXR3 in liver SBRT.
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• Maroun P, Rivin E, Dumas I, et al. Locally advanced cervical cancer in renal trans-
plant patients: a dilemma between control and toxicity. Brachytherapy. 2014 Jan-
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• Mazeron R, Kamsu Kom L, Rivin del Campo E, et al. Comparison between the
ICRU rectal point and modern volumetric parameters in brachytherapy for locally
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• Mazeron R, Aguini N, Rivin E, et al. Improving safety in radiotherapy: The imple-
mentation of the Global Risk Analysis method. Radiother Oncol. 2014 Aug;112(2):205-
11.
• Mazeron R, Castelnau-Marchand P, Dumas I, del Campo ER, et el. Impact of
treatment time and dose escalation on local control in locally advanced cervical cancer
treated by chemoradiation and image-guided pulsed-dose rate adaptive brachytherapy.
Radiother Oncol. 2015 Feb;114(2):257-63.
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• Mazeron R, Castelnau-Marchand P, Escande A, Rivin del Campo E, et al. Tumor
dose-volume response in image-guided adaptive brachytherapy for cervical cancer: A
meta-regression analysis. Brachytherapy 2016 Sep-Oct;15(5):537-42.
• Mazeron R, Gouy S, Chargari C, Rivin del Campo E, et al. Post radiation hysterec-
tomy in locally advanced cervical cancer: Outcomes and dosimetric impact. Radiother
Oncol. 2016 Sep;120(3):460-466.
• Mazeron R, Rivin del Campo E, Haie-Meder C, Chargari C. In Regard to Swanick
et al. Int J Radiat Oncol Biol Phys. 2017 Mar 1;97(3):638.
• Bacorro W, Dumas I, Levy A, Rivin del Campo E, et al. Contribution of image-
guided adaptive brachytherapy to pelvic nodes treatment in locally advanced cervical
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• E Rivin del Campo, S Rivera, M Martínez-Paredes et al. Assessment of the novel
online delineation workshop dummy run approach using FALCON within a European
multicentre trial in cervical cancer (RAIDs). Radiother Oncol. 2017 (in press).
8.5 Participation to conferences within the scope of this
thesis
8.5.1 Oral communications
April 2013 IIIrd Congress of Young Researchers of the University of Cordoba. Advanced
Cervical Cancer: Analysis of Target Volume Delineation. E. Rivin.
April 2013 10th Scientiﬁc and Medical Days of Institut Curie. RAIDs in gynaecology. M.
Kamal and E. Rivin
April 2014 European Society for Radiotherapy & Oncology (ESTRO) 33 Congress. Quality
input of an online delineation workshop in advanced stage cervical cancer. Initial
results. E. Rivin del Campo, S. Rivera, M. Martínez-Paredes, et al.
8.5.2 Poster
November 2016 V Congress of Young Researchers of the University of Cordoba.
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of organs at risk and target volumes within a European Multicentre Trial. E.
Rivin del Campo, et al.
8.5.3 Co-author of oral communications
April 2015 3rd European Society for Radiotherapy & Oncology (ESTRO) Forum. Image-
guided adaptive brachytherapy in cervical cancer: towards a personalization of plan-
ning aims. C. Chargari, R. Mazeron, I. Dumas, P. Castelnau-Marchand, E. Rivin del
Campo, et al.
May 2017 European Society for Radiotherapy & Oncology (ESTRO) 36 Congress. Dose
contribution to pelvic nodes of image guided adaptive brachytherapy in cervical cancer.
W. Bacorro, I. Dumas, A. Levy, E. Rivin del Campo, et al.
June 2017 International Conference in Advances in Radiation Oncology ICARO 2. Nodal
doses during image-guided adaptive brachytherapy for cervical cancer and implication
to simultaneous integrated boost. W. Bacorro, I. Dumas, A. Levy, E. Rivin del
Campo, et al.
8.5.4 Co-author of poster presentation
April 2014 European Society for Radiotherapy & Oncology (ESTRO) 33 Congress. Im-
proving safety in radiotherapy: The implementation of the Global Risk Analysis
method. R. Mazeron, N. Aguini, E. Rivin del Campo, et al. (Young Scientists
Poster Session).
8.5.5 Co-auteur of posters
April 2014 European Society for Radiotherapy & Oncology (ESTRO) 33 Congress.
• Locally advanced cervical cancer in renal transplant patients: A dilemma between
control and toxicity. P. Maroun, E. Rivin, I. Dumas, et al. (e- Poster).
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Mayo Conference. (Institut Curie-all RAIDs partners).
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E. Deutsch, S. Rivera.
• Phase II/III trial in cervical cancer associating the antiviral agent Vistide R© and
radiochemotherapy. E. Rivin, E. Deutsch,M. Mondini.
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